CHEBI ONTOLOGY - ANNOTATIONS |
|
The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
|
Term: | isobutane |
|
Accession: | CHEBI:30363
|
browse the term
|
Definition: | An alkane that is propane substituted by a methyl group at position 2. |
Synonyms: | exact_synonym: | 2-methylpropane |
| related_synonym: | (CH3)2CH-CH3; E943b; Formula=C4H10; InChI=1S/C4H10/c1-4(2)3/h4H,1-3H3; InChIKey=NNPPMTNAJDCUHE-UHFFFAOYSA-N; R-600a; SMILES=CC(C)C |
| xref: | CAS:75-28-5; Gmelin:1301; KEGG:D04623; PMID:24179026; PMID:24464945; Reaxys:1730720; Wikipedia:Isobutane |
|
|
|
G |
Capn1 |
calpain 1 |
multiple interactions |
ISO |
aloxistatin inhibits the reaction [CAPN1 protein results in increased degradation of and results in decreased expression of SMN2 protein alternative form] |
CTD |
PMID:30910806 |
|
NCBI chr 1:203,275,912...203,300,848
Ensembl chr 1:203,277,344...203,300,177
|
|
G |
Capn7 |
calpain 7 |
multiple interactions |
ISO |
aloxistatin inhibits the reaction [CAPN7 protein results in increased degradation of and results in decreased expression of SMN2 protein alternative form] |
CTD |
PMID:30910806 |
|
NCBI chr16:6,545,630...6,581,908
Ensembl chr16:6,545,731...6,581,905
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO EXP |
[aloxistatin co-treated with pepstatin] inhibits the reaction [[vistusertib co-treated with Chloroquine] results in increased activity of CASP3 protein] [Swainsonine co-treated with aloxistatin] results in increased cleavage of CASP3 protein |
CTD |
PMID:26853465 PMID:33186601 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
ISO |
aloxistatin inhibits the reaction [syringic acid analog results in increased secretion of CASP9 protein] |
CTD |
PMID:34523043 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Ctsb |
cathepsin B |
multiple interactions |
ISO |
[aloxistatin co-treated with pepstatin] results in decreased expression of CTSB protein; aloxistatin inhibits the reaction [CTSB protein results in increased degradation of and results in decreased expression of SMN2 protein alternative form] |
CTD |
PMID:30910806 PMID:32186374 |
|
NCBI chr15:37,389,636...37,410,508
Ensembl chr15:37,389,629...37,410,500
|
|
G |
Ctsd |
cathepsin D |
multiple interactions |
ISO |
[aloxistatin co-treated with pepstatin] results in decreased expression of CTSD protein |
CTD |
PMID:32186374 |
|
NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488
|
|
G |
Ctsl |
cathepsin L |
multiple interactions |
ISO |
aloxistatin inhibits the reaction [CTSL protein results in increased degradation of and results in decreased expression of SMN2 protein alternative form] |
CTD |
PMID:30910806 |
|
NCBI chr17:764,370...770,533
Ensembl chr17:764,309...770,548
|
|
G |
Ddx3x |
DEAD-box helicase 3, X-linked |
multiple interactions |
ISO |
aloxistatin inhibits the reaction [[quizartinib co-treated with spautin-1] results in increased degradation of DDX3X protein] |
CTD |
PMID:30821613 |
|
NCBI chr X:9,479,532...9,493,169
Ensembl chr X:9,479,532...9,493,168
|
|
G |
Eif4a1 |
eukaryotic translation initiation factor 4A1 |
multiple interactions |
ISO |
aloxistatin inhibits the reaction [[quizartinib co-treated with spautin-1] results in increased degradation of EIF4A1 protein] |
CTD |
PMID:30821613 |
|
NCBI chr10:54,384,345...54,389,855
Ensembl chr10:54,384,347...54,389,858
|
|
G |
Eif4h |
eukaryotic translation initiation factor 4H |
multiple interactions |
ISO |
aloxistatin inhibits the reaction [[quizartinib co-treated with spautin-1] results in increased degradation of EIF4H protein] |
CTD |
PMID:30821613 |
|
NCBI chr12:22,083,155...22,099,876
Ensembl chr12:22,082,835...22,099,876
|
|
G |
Gapdh |
glyceraldehyde-3-phosphate dehydrogenase |
multiple interactions |
ISO |
aloxistatin inhibits the reaction [syringic acid analog results in increased secretion of GAPDH protein] |
CTD |
PMID:34523043 |
|
NCBI chr 4:157,962,312...157,967,158
Ensembl chr 4:157,962,343...157,966,235
|
|
G |
Lamp2 |
lysosomal-associated membrane protein 2 |
multiple interactions |
ISO |
[aloxistatin co-treated with pepstatin] results in increased expression of LAMP2 protein |
CTD |
PMID:32186374 |
|
NCBI chr X:117,173,097...117,222,090
Ensembl chr X:117,057,606...117,260,522
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
multiple interactions increases lipidation |
ISO |
[aloxistatin co-treated with pepstatin] inhibits the reaction [Biological Factors deficiency results in increased degradation of MAP1LC3B protein modified form]; [aloxistatin co-treated with pepstatin] inhibits the reaction [Biological Factors deficiency results in increased lipidation of MAP1LC3B protein]; [aloxistatin co-treated with pepstatin] inhibits the reaction [Dronabinol results in increased degradation of MAP1LC3B protein modified form]; [aloxistatin co-treated with pepstatin] inhibits the reaction [Dronabinol results in increased lipidation of MAP1LC3B protein]; [aloxistatin co-treated with pepstatin] promotes the reaction [ABTL0812 results in increased expression of and results in increased lipidation of MAP1LC3B protein]; [aloxistatin co-treated with pepstatin] promotes the reaction [Brefeldin A results in increased expression of and results in increased lipidation of MAP1LC3B protein]; [aloxistatin co-treated with pepstatin] promotes the reaction [N-((1R,2S)-2-hydroxy-1-hydroxymethyl-2-(2-tridecyl-1-cyclopropenyl)ethyl)octanamide results in increased expression of and results in increased lipidation of MAP1LC3B protein]; [aloxistatin co-treated with pepstatin] results in decreased degradation of MAP1LC3B protein modified form; aloxistatin promotes the reaction [indatraline results in increased lipidation of MAP1LC3B protein] aloxistatin results in increased lipidation of MAP1LC3B protein [aloxistatin co-treated with pepstatin] inhibits the reaction [Biological Factors deficiency results in increased degradation of MAP1LC3B protein modified form]; [aloxistatin co-treated with pepstatin] inhibits the reaction [Biological Factors deficiency results in increased lipidation of MAP1LC3B protein]; [aloxistatin co-treated with pepstatin] inhibits the reaction [Dronabinol results in increased degradation of MAP1LC3B protein modified form]; [aloxistatin co-treated with pepstatin] inhibits the reaction [Dronabinol results in increased lipidation of MAP1LC3B protein]; [aloxistatin co-treated with pepstatin] results in increased expression of MAP1LC3B protein |
CTD |
PMID:26483381 PMID:27635674 PMID:32397857 PMID:33124469 |
|
NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690 Ensembl chr16:49,665,791...49,677,690
|
|
G |
Sqstm1 |
sequestosome 1 |
multiple interactions increases expression |
ISO |
[aloxistatin co-treated with pepstatin] results in increased expression of SQSTM1 protein; aloxistatin promotes the reaction [indatraline results in increased expression of SQSTM1 protein]; aloxistatin promotes the reaction [Sertraline results in increased expression of SQSTM1 protein] aloxistatin results in increased expression of SQSTM1 protein [aloxistatin co-treated with pepstatin] results in increased expression of SQSTM1 protein; [Dronabinol co-treated with aloxistatin co-treated with pepstatin] results in increased expression of SQSTM1 protein; [HU 211 co-treated with aloxistatin co-treated with pepstatin] results in increased expression of SQSTM1 protein |
CTD |
PMID:26483381 PMID:32186374 PMID:32773031 PMID:33124469 |
|
NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673
|
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
ISO |
1,3-dihydro-1-(1-((4-(6-phenyl-1H-imidazo(4,5-g)quinoxalin-7-yl)phenyl)methyl)-4-piperidinyl)-2H-benzimidazol-2-one promotes the reaction [N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [polyhexamethyleneguanidine results in increased expression of ACTA2 protein]]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [polyhexamethyleneguanidine results in increased expression of ACTA2 protein]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester promotes the reaction [1,3-dihydro-1-(1-((4-(6-phenyl-1H-imidazo(4,5-g)quinoxalin-7-yl)phenyl)methyl)-4-piperidinyl)-2H-benzimidazol-2-one inhibits the reaction [polyhexamethyleneguanidine results in increased expression of ACTA2 protein]] |
CTD |
PMID:31348943 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
1,3-dihydro-1-(1-((4-(6-phenyl-1H-imidazo(4,5-g)quinoxalin-7-yl)phenyl)methyl)-4-piperidinyl)-2H-benzimidazol-2-one promotes the reaction [N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [polyhexamethyleneguanidine results in increased phosphorylation of AKT1 protein]]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [polyhexamethyleneguanidine results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:31348943 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Tunicamycin results in increased secretion of APP protein modified form] |
CTD |
PMID:22115781 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression multiple interactions |
EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in increased expression of BAX protein N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [[Polyribonucleotides results in decreased expression of MIR141 mRNA] inhibits the reaction [Palmitic Acid results in increased expression of BAX protein]] |
CTD |
PMID:21209419 PMID:34897970 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression multiple interactions |
EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of BCL2 protein N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [[Polyribonucleotides results in decreased expression of MIR141 mRNA] inhibits the reaction [Palmitic Acid results in decreased expression of BCL2 protein]] |
CTD |
PMID:21209419 PMID:34897970 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bmp6 |
bone morphogenetic protein 6 |
multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [BMP6 protein results in increased expression of KRT1 mRNA]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [BMP6 protein results in increased expression of KRT10 mRNA] |
CTD |
PMID:23566955 |
|
NCBI chr17:26,318,121...26,469,691
Ensembl chr17:26,318,569...26,470,365
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [[Polyribonucleotides results in decreased expression of MIR141 mRNA] inhibits the reaction [Palmitic Acid results in increased expression of CASP3 protein modified form]]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in increased expression of and results in increased activity of CASP3 protein |
CTD |
PMID:21209419 PMID:34897970 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [[Polyribonucleotides results in decreased expression of MIR141 mRNA] inhibits the reaction [Palmitic Acid results in increased expression of CASP9 protein modified form]] |
CTD |
PMID:34897970 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [baicalein results in increased expression of CCND1 mRNA]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [baicalin results in increased expression of CCND1 mRNA] |
CTD |
PMID:19160421 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Cdh1 |
cadherin 1 |
multiple interactions |
ISO |
[N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester co-treated with 1,3-dihydro-1-(1-((4-(6-phenyl-1H-imidazo(4,5-g)quinoxalin-7-yl)phenyl)methyl)-4-piperidinyl)-2H-benzimidazol-2-one] inhibits the reaction [polyhexamethyleneguanidine results in decreased expression of CDH1 protein]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Cadmium Chloride results in increased secretion of CDH1 protein]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Cadmium results in increased cleavage of CDH1 protein] |
CTD |
PMID:18791180 PMID:31348943 |
|
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Cdh2 |
cadherin 2 |
multiple interactions |
EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Cadmium Chloride results in increased cleavage of CDH2 protein] |
CTD |
PMID:23876460 |
|
NCBI chr18:7,776,704...7,990,934
Ensembl chr18:7,776,704...7,990,167
|
|
G |
Csf1 |
colony stimulating factor 1 |
multiple interactions |
EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of CSF1 mRNA] |
CTD |
PMID:24223152 |
|
NCBI chr 2:195,377,215...195,396,608
Ensembl chr 2:195,377,215...195,411,704
|
|
G |
Eno2 |
enolase 2 |
multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester promotes the reaction [rhodioloside results in increased expression of ENO2 mRNA] |
CTD |
PMID:24929042 |
|
NCBI chr 4:157,572,085...157,580,971
Ensembl chr 4:157,572,088...157,580,980
|
|
G |
Flt1 |
Fms related receptor tyrosine kinase 1 |
multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester promotes the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of FLT1 protein] |
CTD |
PMID:21843347 |
|
NCBI chr12:7,296,899...7,468,626
Ensembl chr12:7,297,292...7,468,626
|
|
G |
Foxo3 |
forkhead box O3 |
multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester promotes the reaction [Hydrogen Peroxide results in increased expression of FOXO3 protein] |
CTD |
PMID:25108166 |
|
NCBI chr20:45,669,708...45,764,606
Ensembl chr20:45,672,995...45,764,561
|
|
G |
Hes1 |
hes family bHLH transcription factor 1 |
multiple interactions decreases expression |
ISO EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [baicalein results in increased expression of HES1 mRNA]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [baicalin results in increased expression of HES1 mRNA]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Hydrogen Peroxide results in increased expression of HES1 protein] N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of HES1 protein N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of HES1 mRNA]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [tetrabromobisphenol A results in increased expression of HES1 mRNA] N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of HES1 protein] |
CTD |
PMID:19160421 PMID:24223152 PMID:25005833 PMID:25108166 PMID:32041402 PMID:36988346 More...
|
|
NCBI chr11:70,705,763...70,708,176
Ensembl chr11:70,705,764...70,708,192
|
|
G |
Hey1 |
hes-related family bHLH transcription factor with YRPW motif 1 |
multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [baicalein results in increased expression of HEY1 mRNA]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [baicalin results in increased expression of HEY1 mRNA] |
CTD |
PMID:19160421 |
|
NCBI chr 2:93,096,605...93,100,316
Ensembl chr 2:93,095,498...93,100,312
|
|
G |
Hey2 |
hes-related family bHLH transcription factor with YRPW motif 2 |
multiple interactions |
ISO EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [baicalein results in increased expression of HEY2 mRNA]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [baicalin results in increased expression of HEY2 mRNA]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Niclosamide results in increased expression of HEY2 mRNA] N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [tetrabromobisphenol A results in increased expression of HEY2 mRNA] |
CTD |
PMID:19160421 PMID:32041402 |
|
NCBI chr 1:26,822,131...26,832,218
Ensembl chr 1:26,822,131...26,832,218
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester promotes the reaction [Hydrogen Peroxide results in increased expression of HIF1A protein] |
CTD |
PMID:25108166 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hmgb1 |
high mobility group box 1 |
multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of HMGB1 protein] |
CTD |
PMID:21843347 |
|
NCBI chr12:5,972,950...5,979,658
Ensembl chr12:5,901,586...5,978,565 Ensembl chr16:5,901,586...5,978,565
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of IL10 mRNA] |
CTD |
PMID:24223152 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of IL1B protein]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of IL1B protein] N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Diethylhexyl Phthalate results in increased expression of IL1B protein]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of IL1B mRNA] |
CTD |
PMID:21843347 PMID:24223152 PMID:36988346 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of IL6 mRNA] N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of IL6 protein] |
CTD |
PMID:21843347 PMID:24223152 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Itgam |
integrin subunit alpha M |
multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [4-amino-2-trifluoromethyl-phenyl retinate results in increased expression of ITGAM protein] |
CTD |
PMID:28130038 |
|
NCBI chr 1:182,659,047...182,709,501
Ensembl chr 1:182,659,000...182,709,503
|
|
G |
Ivl |
involucrin |
decreases expression |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of IVL mRNA; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of IVL protein |
CTD |
PMID:18633435 |
|
NCBI chr 2:178,146,694...178,160,807
Ensembl chr 2:178,147,061...178,149,100
|
|
G |
Jag1 |
jagged canonical Notch ligand 1 |
decreases expression |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of JAG1 mRNA; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of JAG1 protein |
CTD |
PMID:18633435 |
|
NCBI chr 3:124,406,783...124,442,220
Ensembl chr 3:124,406,794...124,442,209
|
|
G |
Krt1 |
keratin 1 |
multiple interactions decreases expression |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [BMP6 protein results in increased expression of KRT1 mRNA]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [U 0126 results in increased expression of KRT1 mRNA] N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of KRT1 mRNA |
CTD |
PMID:18633435 PMID:23566955 |
|
NCBI chr 7:132,976,618...132,981,844
Ensembl chr 7:132,976,620...132,981,844
|
|
G |
Krt10 |
keratin 10 |
multiple interactions decreases expression |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [BMP6 protein results in increased expression of KRT10 mRNA]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [U 0126 results in increased expression of KRT10 mRNA] N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of KRT10 mRNA; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of KRT10 protein |
CTD |
PMID:18633435 PMID:23566955 |
|
NCBI chr10:84,338,695...84,343,279
Ensembl chr10:84,338,706...84,343,701
|
|
G |
Lgr5 |
leucine rich repeat containing G protein coupled receptor 5 |
multiple interactions |
EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [tetrabromobisphenol A results in increased expression of LGR5 mRNA] |
CTD |
PMID:32041402 |
|
NCBI chr 7:51,087,059...51,221,882
Ensembl chr 7:51,088,239...51,222,446
|
|
G |
Map2 |
microtubule-associated protein 2 |
multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester promotes the reaction [rhodioloside results in increased expression of MAP2 mRNA] |
CTD |
PMID:24929042 |
|
NCBI chr 9:67,723,422...67,981,886
Ensembl chr 9:67,723,371...67,979,809
|
|
G |
Mdm2 |
MDM2 proto-oncogene |
multiple interactions increases expression |
ISO |
Hydrogen Peroxide inhibits the reaction [N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in increased expression of MDM2 protein] |
CTD |
PMID:25005833 |
|
NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915
|
|
G |
Mir141 |
microRNA 141 |
multiple interactions |
EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [[Polyribonucleotides results in decreased expression of MIR141 mRNA] inhibits the reaction [Palmitic Acid results in decreased expression of BCL2 protein]]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [[Polyribonucleotides results in decreased expression of MIR141 mRNA] inhibits the reaction [Palmitic Acid results in increased expression of BAX protein]]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [[Polyribonucleotides results in decreased expression of MIR141 mRNA] inhibits the reaction [Palmitic Acid results in increased expression of CASP3 protein modified form]]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [[Polyribonucleotides results in decreased expression of MIR141 mRNA] inhibits the reaction [Palmitic Acid results in increased expression of CASP9 protein modified form]] |
CTD |
PMID:34897970 |
|
NCBI chr 4:157,523,239...157,523,332
Ensembl chr 4:157,523,239...157,523,332
|
|
G |
Myd88 |
MYD88, innate immune signal transduction adaptor |
multiple interactions |
ISO EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of MYD88 protein] N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of MYD88 mRNA] |
CTD |
PMID:24223152 |
|
NCBI chr 8:119,074,439...119,078,508
Ensembl chr 8:119,074,437...119,079,415
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of NOS2 protein] N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of NOS2 mRNA] |
CTD |
PMID:24223152 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Notch1 |
notch receptor 1 |
multiple interactions decreases expression |
ISO EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [4-amino-2-trifluoromethyl-phenyl retinate results in increased expression of NOTCH1 protein]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Cadmium Chloride results in increased cleavage of NOTCH1 protein]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Hydrogen Peroxide results in increased cleavage of NOTCH1 protein]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [phenethyl isothiocyanate results in increased cleavage of and results in increased activity of NOTCH1 protein]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [polyhexamethyleneguanidine results in increased cleavage of NOTCH1 protein]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester promotes the reaction [1,3-dihydro-1-(1-((4-(6-phenyl-1H-imidazo(4,5-g)quinoxalin-7-yl)phenyl)methyl)-4-piperidinyl)-2H-benzimidazol-2-one inhibits the reaction [polyhexamethyleneguanidine results in increased cleavage of NOTCH1 protein]]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased cleavage of and results in decreased activity of NOTCH1 protein N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of NOTCH1 protein N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [mono-(2-ethylhexyl)phthalate results in increased expression of NOTCH1 protein] N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency affects the localization of NOTCH1 protein modified form]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Tunicamycin results in increased cleavage of NOTCH1 protein]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester promotes the reaction [Oxygen deficiency results in increased expression of NOTCH1 protein] N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of NOTCH1 protein modified form |
CTD |
PMID:18633435 PMID:22039516 PMID:22115781 PMID:24223152 PMID:25108166 PMID:25118938 PMID:28130038 PMID:31348943 PMID:36988346 More...
|
|
NCBI chr 3:9,277,955...9,323,531
Ensembl chr 3:9,278,086...9,323,531
|
|
G |
Notch2 |
notch receptor 2 |
multiple interactions decreases expression |
ISO EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased cleavage of and results in decreased activity of NOTCH2 protein N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [mono-(2-ethylhexyl)phthalate results in increased expression of NOTCH2 protein] N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of NOTCH2 protein |
CTD |
PMID:22039516 PMID:36988346 |
|
NCBI chr 2:185,610,594...185,744,088
Ensembl chr 2:185,610,589...185,744,088
|
|
G |
Notch3 |
notch receptor 3 |
decreases expression |
EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of NOTCH3 protein |
CTD |
PMID:36988346 |
|
NCBI chr 7:11,132,984...11,184,025
Ensembl chr 7:11,133,706...11,184,025
|
|
G |
Notch4 |
notch receptor 4 |
decreases expression |
EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of NOTCH4 protein |
CTD |
PMID:36988346 |
|
NCBI chr20:4,160,362...4,184,466
Ensembl chr20:4,160,445...4,184,465
|
|
G |
Numb |
NUMB, endocytic adaptor protein |
increases expression |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in increased expression of NUMB protein |
CTD |
PMID:25005833 |
|
NCBI chr 6:103,431,400...103,553,422
Ensembl chr 6:103,431,400...103,553,354
|
|
G |
Pml |
PML nuclear body scaffold |
multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [4-amino-2-trifluoromethyl-phenyl retinate results in increased degradation of [PML protein mutant form binds to RARA protein mutant form]] |
CTD |
PMID:28130038 |
|
NCBI chr 8:58,627,347...58,661,927
Ensembl chr 8:58,628,837...58,658,971
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
increases expression multiple interactions |
EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in increased expression of PPARA protein N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Diethylhexyl Phthalate results in decreased expression of PPARA protein] |
CTD |
PMID:36988346 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Cadmium results in increased expression of PTGS2 mRNA] |
CTD |
PMID:18791180 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rara |
retinoic acid receptor, alpha |
multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [4-amino-2-trifluoromethyl-phenyl retinate results in increased degradation of [PML protein mutant form binds to RARA protein mutant form]] |
CTD |
PMID:28130038 |
|
NCBI chr10:83,883,490...83,928,932
Ensembl chr10:83,893,384...83,928,142
|
|
G |
Rbpj |
recombination signal binding protein for immunoglobulin kappa J region |
multiple interactions increases expression |
EXP ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of RBPJ mRNA] N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in increased expression of RBPJ protein N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Cycloheximide results in decreased expression of RBPJ protein] |
CTD |
PMID:22302987 PMID:24223152 |
|
NCBI chr14:57,338,493...57,523,330
Ensembl chr14:57,338,507...57,523,353
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency affects the localization of RELA protein modified form]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of RELA protein] |
CTD |
PMID:24223152 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of TGFB1 mRNA] |
CTD |
PMID:24223152 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tlr4 |
toll-like receptor 4 |
multiple interactions |
EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of TLR4 mRNA] |
CTD |
PMID:24223152 |
|
NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of TNF protein] N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of TNF mRNA] |
CTD |
PMID:24223152 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tp53 |
tumor protein p53 |
decreases expression multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of TP53 protein Hydrogen Peroxide inhibits the reaction [N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester results in decreased expression of TP53 protein] |
CTD |
PMID:25005833 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Traf6 |
TNF receptor associated factor 6 |
multiple interactions |
ISO EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of TRAF6 protein] N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Oxygen deficiency results in increased expression of TRAF6 mRNA] |
CTD |
PMID:24223152 |
|
NCBI chr 3:87,963,517...87,988,316
Ensembl chr 3:87,963,514...87,983,507
|
|
G |
Tubb3 |
tubulin, beta 3 class III |
multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester promotes the reaction [rhodioloside results in increased expression of TUBB3 mRNA] |
CTD |
PMID:24929042 |
|
NCBI chr19:51,457,187...51,466,243
Ensembl chr19:51,457,184...51,466,243
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of VEGFA protein] |
CTD |
PMID:21843347 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Vil1 |
villin 1 |
multiple interactions |
EXP |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [tetrabromobisphenol A results in increased expression of VIL1 mRNA] |
CTD |
PMID:32041402 |
|
NCBI chr 9:75,991,141...76,018,860
Ensembl chr 9:75,991,141...76,018,858
|
|
|
G |
A4galt |
alpha 1,4-galactosyltransferase |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of A4GALT mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 7:114,368,525...114,392,872
Ensembl chr 7:114,368,276...114,396,071
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ABCG2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Adamts1 |
ADAM metallopeptidase with thrombospondin type 1 motif, 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of ADAMTS1 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of ADAMTS1 mRNA] [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein affects the expression of ADAMTS1 mRNA] |
CTD |
PMID:33316053 PMID:37552060 |
|
NCBI chr11:24,932,227...24,941,068
Ensembl chr11:24,931,761...24,941,103
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with Diethylhexyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate] results in increased expression of ADIPOQ mRNA; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with diisononyl phthalate co-treated with butylbenzyl phthalate] results in decreased secretion of ADIPOQ protein |
CTD |
PMID:37021957 PMID:38954831 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Adrb3 |
adrenoceptor beta 3 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with Diethylhexyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate] results in decreased expression of ADRB3 mRNA |
CTD |
PMID:37021957 |
|
NCBI chr16:64,839,820...64,844,552
Ensembl chr16:64,841,788...64,844,552
|
|
G |
Ak5 |
adenylate kinase 5 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of AK5 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 2:241,397,297...241,581,483
Ensembl chr 2:241,397,297...241,581,458
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of ALDH1A1 mRNA |
CTD |
PMID:30768133 |
|
NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961
|
|
G |
Aldh2 |
aldehyde dehydrogenase 2 family member |
decreases expression |
EXP |
diisobutyl phthalate results in decreased expression of ALDH2 mRNA |
CTD |
PMID:33983380 |
|
NCBI chr12:34,949,549...34,982,527
Ensembl chr12:34,901,219...34,982,521
|
|
G |
Aldoc |
aldolase, fructose-bisphosphate C |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ALDOC mRNA; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of ALDOC protein |
CTD |
PMID:31199487 PMID:37690569 |
|
NCBI chr10:63,217,477...63,221,066
Ensembl chr10:63,217,451...63,221,066
|
|
G |
Amhr2 |
anti-Mullerian hormone receptor type 2 |
increases expression |
EXP |
diisobutyl phthalate results in increased expression of AMHR2 mRNA |
CTD |
PMID:22112501 |
|
NCBI chr 7:133,579,152...133,588,874
Ensembl chr 7:133,579,393...133,588,258
|
|
G |
Angpt2 |
angiopoietin 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with diisononyl phthalate co-treated with butylbenzyl phthalate] results in decreased secretion of ANGPT2 protein |
CTD |
PMID:38954831 |
|
NCBI chr16:71,088,364...71,138,805
Ensembl chr16:71,088,364...71,138,804
|
|
G |
Angptl3 |
angiopoietin-like 3 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with diisononyl phthalate co-treated with butylbenzyl phthalate] results in decreased secretion of ANGPTL3 protein |
CTD |
PMID:38954831 |
|
NCBI chr 5:113,703,007...113,710,044
Ensembl chr 5:113,703,012...113,709,957
|
|
G |
Ar |
androgen receptor |
affects binding multiple interactions |
EXP ISO |
diisobutyl phthalate binds to AR protein diisobutyl phthalate inhibits the reaction [Dihydrotestosterone binds to and results in increased activity of AR protein]; diisobutyl phthalate inhibits the reaction [Dihydrotestosterone results in increased activity of AR protein] |
CTD |
PMID:14565775 PMID:15840436 PMID:28571686 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Arnt2 |
aryl hydrocarbon receptor nuclear translocator 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ARNT2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:138,236,235...138,392,868
Ensembl chr 1:138,189,940...138,393,153
|
|
G |
Astn1 |
astrotactin 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ASTN1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr13:70,537,423...70,855,440
Ensembl chr13:70,537,703...70,855,440
|
|
G |
Astn2 |
astrotactin 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ASTN2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 5:78,758,142...79,744,021
Ensembl chr 5:78,758,142...79,748,273
|
|
G |
Atp1a3 |
ATPase Na+/K+ transporting subunit alpha 3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ATP1A3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:80,572,790...80,601,936
Ensembl chr 1:80,572,796...80,601,918
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with Diethylhexyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate] results in increased expression of BAX mRNA; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of BAX mRNA |
CTD |
PMID:28013214 PMID:37021957 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcat1 |
branched chain amino acid transaminase 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of BCAT1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 4:177,964,834...178,046,573
Ensembl chr 4:177,964,834...178,046,597
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO EXP |
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with Diethylhexyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate] results in increased expression of BCL2 mRNA; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of BCL2 mRNA |
CTD |
PMID:28013214 PMID:35762964 PMID:37021957 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l10 |
Bcl2-like 10 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with Diethylhexyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate] results in increased expression of BCL2L10 mRNA |
CTD |
PMID:37021957 |
|
NCBI chr 8:76,107,326...76,113,373
Ensembl chr 8:76,107,326...76,113,367
|
|
G |
Bend6 |
BEN domain containing 6 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of BEND6 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 9:36,081,033...36,135,309
Ensembl chr 9:36,081,484...36,135,228
|
|
G |
Bpgm |
bisphosphoglycerate mutase |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of BPGM mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 4:63,139,730...63,168,581
Ensembl chr 4:63,140,018...63,168,581
|
|
G |
C5 |
complement C5 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with diisononyl phthalate co-treated with butylbenzyl phthalate] affects the expression of and affects the secretion of C5 protein |
CTD |
PMID:38954831 |
|
NCBI chr 3:18,270,696...18,361,994
Ensembl chr 3:18,270,696...18,361,994
|
|
G |
Cacng7 |
calcium voltage-gated channel auxiliary subunit gamma 7 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CACNG7 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:65,800,059...65,831,246
Ensembl chr 1:65,800,355...65,831,006
|
|
G |
Cadm3 |
cell adhesion molecule 3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CADM3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr13:85,784,785...85,817,412
Ensembl chr13:85,786,483...85,817,749
|
|
G |
Cadps |
calcium dependent secretion activator |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CADPS mRNA |
CTD |
PMID:31199487 |
|
NCBI chr15:12,289,803...12,742,786
Ensembl chr15:12,290,262...12,742,779
|
|
G |
Camk4 |
calcium/calmodulin-dependent protein kinase IV |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CAMK4 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr18:24,582,988...24,811,918
Ensembl chr18:24,585,269...24,802,487
|
|
G |
Casp2 |
caspase 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with Diethylhexyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate] results in increased expression of CASP2 mRNA |
CTD |
PMID:37021957 |
|
NCBI chr 4:71,149,632...71,167,388
Ensembl chr 4:71,149,669...71,167,379
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisobutyl phthalate co-treated with diisononyl phthalate] results in decreased expression of CASP3 mRNA |
CTD |
PMID:37839492 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CASP8 mRNA |
CTD |
PMID:28013214 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CAT mRNA |
CTD |
PMID:28013214 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with Diethylhexyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate] results in increased expression of CCL2 mRNA |
CTD |
PMID:37021957 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with Diethylhexyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate] results in increased expression of CCL5 mRNA |
CTD |
PMID:37021957 |
|
NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Ccnd2 |
cyclin D2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CCND2 mRNA |
CTD |
PMID:28013214 |
|
NCBI chr 4:159,966,883...159,989,261
Ensembl chr 4:159,962,363...159,989,495
|
|
G |
Cd93 |
CD93 molecule |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with diisononyl phthalate co-treated with butylbenzyl phthalate] results in decreased secretion of CD93 protein |
CTD |
PMID:38954831 |
|
NCBI chr 3:135,891,859...135,898,378
Ensembl chr 3:135,891,859...135,898,378
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of CDK4 mRNA |
CTD |
PMID:35762964 |
|
NCBI chr 7:62,886,124...62,889,562
Ensembl chr 7:62,883,105...62,942,403
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions |
ISO EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of CDKN1A mRNA] [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CDKN1A mRNA |
CTD |
PMID:33316053 PMID:35762964 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisobutyl phthalate co-treated with diisononyl phthalate] results in decreased expression of CDKN1B mRNA |
CTD |
PMID:37839492 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of CDKN2A mRNA |
CTD |
PMID:28013214 |
|
NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with Diethylhexyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate] results in increased expression of CEBPA mRNA |
CTD |
PMID:37021957 |
|
NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412
|
|
G |
Celsr3 |
cadherin, EGF LAG seven-pass G-type receptor 3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CELSR3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 8:109,530,597...109,558,360
Ensembl chr 8:109,530,641...109,558,354
|
|
G |
Cga |
glycoprotein hormones, alpha polypeptide |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of ADAMTS1 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of EDN2 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of MMP9 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of PGR mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of PLAT mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of ADAMTS1 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of CDKN1A mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of IL6 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of PTGS2 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of SERPINB2 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of SERPINE1 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of TIMP1 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of WNT4 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] promotes the reaction [CGA protein results in increased expression of MMP14 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] promotes the reaction [CGA protein results in increased expression of MMP16 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] promotes the reaction [CGA protein results in increased expression of SLCO2A1 mRNA] [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein affects the expression of ADAMTS1 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of CXCR4 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of CYP11A1 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of HSD3B2 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of PTX3 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of PGR mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of RGS2 mRNA]; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of STAR mRNA]; Cyclic AMP inhibits the reaction [[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of PGR mRNA]] |
CTD |
PMID:33316053 PMID:37552060 |
|
NCBI chr 5:49,486,915...49,499,192
Ensembl chr 5:49,487,068...49,499,191
|
|
G |
Chga |
chromogranin A |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CHGA mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 6:121,696,051...121,707,399
Ensembl chr 6:121,696,051...121,707,398
|
|
G |
Chgb |
chromogranin B |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CHGB mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 3:120,043,824...120,057,169
Ensembl chr 3:120,043,738...120,057,166
|
|
G |
Cited1 |
Cbp/p300-interacting transactivator with Glu/Asp-rich carboxy-terminal domain 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CITED1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr X:67,350,376...67,355,072
Ensembl chr X:67,350,373...67,355,162
|
|
G |
Clstn3 |
calsyntenin 3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CLSTN3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 4:157,331,494...157,364,769
Ensembl chr 4:157,331,494...157,364,769
|
|
G |
Cntnap1 |
contactin associated protein 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CNTNAP1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr10:86,109,850...86,125,612
Ensembl chr10:86,111,643...86,125,611
|
|
G |
Col18a1 |
collagen type XVIII alpha 1 chain |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with diisononyl phthalate co-treated with butylbenzyl phthalate] results in decreased secretion of COL18A1 protein |
CTD |
PMID:38954831 |
|
NCBI chr20:11,474,104...11,582,593
Ensembl chr20:11,474,104...11,582,593
|
|
G |
Crmp1 |
collapsin response mediator protein 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CRMP1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr14:73,509,933...73,556,192
Ensembl chr14:73,509,933...73,556,177
|
|
G |
Crp |
C-reactive protein |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with diisononyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of CRP protein |
CTD |
PMID:38954831 |
|
NCBI chr13:85,135,384...85,175,178
Ensembl chr13:85,124,977...85,175,178
|
|
G |
Csf1 |
colony stimulating factor 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with diisononyl phthalate co-treated with butylbenzyl phthalate] affects the expression of and affects the secretion of CSF1 protein |
CTD |
PMID:38954831 |
|
NCBI chr 2:195,377,215...195,396,608
Ensembl chr 2:195,377,215...195,411,704
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with diisononyl phthalate co-treated with butylbenzyl phthalate] affects the expression of and affects the secretion of CXCL12 protein |
CTD |
PMID:38954831 |
|
NCBI chr 4:150,388,326...150,401,173
Ensembl chr 4:150,388,325...150,401,168
|
|
G |
Cxcl13 |
C-X-C motif chemokine ligand 13 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with diisononyl phthalate co-treated with butylbenzyl phthalate] affects the expression of and affects the secretion of CXCL13 protein |
CTD |
PMID:38954831 |
|
NCBI chr14:13,608,894...13,613,965
Ensembl chr14:13,608,902...13,613,933
|
|
G |
Cxcr4 |
C-X-C motif chemokine receptor 4 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of CXCR4 mRNA] |
CTD |
PMID:37552060 |
|
NCBI chr13:40,077,976...40,081,883
Ensembl chr13:40,077,976...40,081,883
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
decreases expression multiple interactions |
EXP ISO |
diisobutyl phthalate results in decreased expression of CYP11A1 mRNA; diisobutyl phthalate results in decreased expression of CYP11A1 protein [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of CYP11A1 mRNA] [diethyl phthalate co-treated with diisobutyl phthalate] results in decreased expression of CYP11A1 mRNA; [diisobutyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate] results in decreased expression of CYP11A1 mRNA [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CYP11A1 mRNA; [Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diethyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate] results in decreased expression of CYP11A1 mRNA; [Diethylhexyl Phthalate co-treated with diethyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate] results in decreased expression of CYP11A1 mRNA |
CTD |
PMID:16458459 PMID:21633115 PMID:22112501 PMID:28013214 PMID:30802670 PMID:33983380 PMID:34597818 PMID:37552060 PMID:37788136 More...
|
|
NCBI chr 8:58,422,807...58,434,342
Ensembl chr 8:58,404,669...58,434,338
|
|
G |
Cyp11b2 |
cytochrome P450, family 11, subfamily b, polypeptide 2 |
multiple interactions decreases expression |
EXP |
[diethyl phthalate co-treated with diisobutyl phthalate] results in decreased expression of CYP11B1 mRNA diisobutyl phthalate results in decreased expression of CYP11B1 mRNA |
CTD |
PMID:22112501 PMID:33983380 |
|
NCBI chr 7:106,838,590...106,845,004
Ensembl chr 7:106,838,590...106,845,004
|
|
G |
Cyp11b3 |
cytochrome P450, family 11, subfamily b, polypeptide 3 |
decreases expression multiple interactions |
EXP |
diisobutyl phthalate results in decreased expression of CYP11B2 mRNA [diethyl phthalate co-treated with diisobutyl phthalate] results in decreased expression of CYP11B2 mRNA |
CTD |
PMID:33983380 |
|
NCBI chr 7:106,808,559...106,814,048
Ensembl chr 7:106,808,559...106,814,048
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
decreases expression multiple interactions |
EXP ISO |
diisobutyl phthalate results in decreased expression of CYP17A1 mRNA [diethyl phthalate co-treated with diisobutyl phthalate] results in decreased expression of CYP17A1 mRNA; [diisobutyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate] results in decreased expression of CYP17A1 mRNA [Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diethyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate] results in decreased expression of CYP17A1 mRNA |
CTD |
PMID:22112501 PMID:28655647 PMID:30802670 PMID:33983380 PMID:37788136 |
|
NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CYP19A1 mRNA; [Diethylhexyl Phthalate co-treated with diethyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate] results in decreased expression of CYP19A1 mRNA |
CTD |
PMID:28013214 PMID:34597818 |
|
NCBI chr 8:54,552,978...54,580,375
Ensembl chr 8:54,553,165...54,580,758
|
|
G |
Cyp26b1 |
cytochrome P450, family 26, subfamily b, polypeptide 1 |
multiple interactions |
EXP |
[diisobutyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate] results in increased expression of CYP26B1 mRNA |
CTD |
PMID:37788136 |
|
NCBI chr 4:117,041,808...117,058,628
Ensembl chr 4:117,041,808...117,058,628
|
|
G |
Cyp51 |
cytochrome P450, family 51 |
decreases expression |
EXP |
diisobutyl phthalate results in decreased expression of CYP51 mRNA |
CTD |
PMID:33983380 |
|
NCBI chr 4:30,036,956...30,055,410
Ensembl chr 4:30,036,865...30,055,410 Ensembl chr 6:30,036,865...30,055,410
|
|
G |
Dclk3 |
doublecortin-like kinase 3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of DCLK3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 8:111,401,544...111,453,999
Ensembl chr 8:111,401,358...111,453,999
|
|
G |
Ddc |
dopa decarboxylase |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of DDC mRNA |
CTD |
PMID:31199487 |
|
NCBI chr14:86,378,685...86,469,189
Ensembl chr14:86,378,685...86,469,208
|
|
G |
Dhcr7 |
7-dehydrocholesterol reductase |
multiple interactions decreases expression |
EXP |
[diethyl phthalate co-treated with diisobutyl phthalate] results in decreased expression of DHCR7 mRNA diisobutyl phthalate results in decreased expression of DHCR7 mRNA |
CTD |
PMID:33983380 |
|
NCBI chr 1:199,015,081...199,031,055
Ensembl chr 1:199,015,081...199,031,055
|
|
G |
Dock3 |
dedicator of cyto-kinesis 3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of DOCK3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 8:107,552,462...107,903,527
Ensembl chr 8:107,552,463...107,903,514
|
|
G |
Dpf1 |
double PHD fingers 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of DPF1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:84,602,212...84,615,954
Ensembl chr 1:84,602,336...84,615,950
|
|
G |
Dync1i1 |
dynein cytoplasmic 1 intermediate chain 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of DYNC1I1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 4:33,852,597...34,166,159
Ensembl chr 4:33,852,927...34,166,149
|
|
G |
Ebp |
EBP, cholestenol delta-isomerase |
decreases expression |
EXP |
diisobutyl phthalate results in decreased expression of EBP mRNA |
CTD |
PMID:33983380 |
|
NCBI chr X:14,299,427...14,305,826
Ensembl chr X:14,299,448...14,305,826
|
|
G |
Ece2 |
endothelin-converting enzyme 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ECE2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr11:80,259,130...80,278,446
Ensembl chr11:80,263,162...80,278,428
|
|
G |
Edn1 |
endothelin 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of EDN1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Edn2 |
endothelin 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of EDN2 mRNA] |
CTD |
PMID:33316053 |
|
NCBI chr 5:133,751,316...133,756,814
Ensembl chr 5:133,751,217...133,756,814
|
|
G |
Elmod1 |
ELMO domain containing 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ELMOD1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 8:54,298,363...54,355,348
Ensembl chr 8:54,298,363...54,355,140
|
|
G |
Emx2 |
empty spiracles homeobox 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of EMX2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:258,626,584...258,633,594
Ensembl chr 1:258,626,584...258,633,594
|
|
G |
Epdr1 |
ependymin related 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of EPDR1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr17:45,333,932...45,358,597
Ensembl chr17:45,333,956...45,358,594
|
|
G |
Espn |
espin |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ESPN mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 5:162,626,560...162,660,439
Ensembl chr 5:162,626,560...162,660,256
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions increases activity |
ISO |
diisobutyl phthalate binds to and results in increased activity of ESR1 protein; diisobutyl phthalate inhibits the reaction [Estradiol results in increased activity of ESR1 protein]; Tamoxifen inhibits the reaction [diisobutyl phthalate binds to and results in increased activity of ESR1 protein] diisobutyl phthalate results in increased activity of ESR1 protein [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ESR1 mRNA |
CTD |
PMID:15840436 PMID:27633901 PMID:28013214 PMID:28571686 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions increases activity |
ISO |
diisobutyl phthalate binds to and results in increased activity of ESR2 protein; diisobutyl phthalate inhibits the reaction [Estradiol results in increased activity of ESR2 protein] diisobutyl phthalate results in increased activity of ESR2 protein |
CTD |
PMID:27633901 PMID:28571686 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Fabp5 |
fatty acid binding protein 5 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of FABP5 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 2:91,765,056...91,768,716
Ensembl chr 2:91,765,056...91,853,773
|
|
G |
Fam163a |
family with sequence similarity 163, member A |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of FAM163A mRNA |
CTD |
PMID:31199487 |
|
NCBI chr13:68,262,867...68,341,323
Ensembl chr13:68,262,872...68,341,049
|
|
G |
Fdps |
farnesyl diphosphate synthase |
decreases expression |
EXP |
diisobutyl phthalate results in decreased expression of FDPS mRNA |
CTD |
PMID:33983380 |
|
NCBI chr 2:174,497,402...174,507,031
Ensembl chr 2:174,486,665...174,507,776
|
|
G |
Fez1 |
fasciculation and elongation protein zeta 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of FEZ1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 8:36,544,462...36,589,684
Ensembl chr 8:36,544,535...36,589,683
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with Diethylhexyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate] results in increased expression of FGF2 mRNA |
CTD |
PMID:37021957 |
|
NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221
|
|
G |
Fkbp1b |
FKBP prolyl isomerase 1B |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of FKBP1B mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 6:27,832,128...27,850,600
Ensembl chr 6:27,838,802...27,848,653
|
|
G |
Flg |
filaggrin |
multiple interactions |
ISO |
[FLG gene polymorphism affects the susceptibility to diisobutyl phthalate] which affects the abundance of mono-isobutyl phthalate |
CTD |
PMID:24380925 |
|
NCBI chr 2:178,884,793...178,912,986
|
|
G |
Fshb |
follicle stimulating hormone subunit beta |
multiple interactions |
ISO |
[Diethylhexyl Phthalate co-treated with diethyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate] results in decreased expression of FSHB protein |
CTD |
PMID:34597818 |
|
NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370
|
|
G |
Fshr |
follicle stimulating hormone receptor |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of FSHR mRNA |
CTD |
PMID:28013214 |
|
NCBI chr 6:5,198,825...5,406,785
Ensembl chr 6:5,198,825...5,406,785
|
|
G |
Fxyd7 |
FXYD domain-containing ion transport regulator 7 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of FXYD7 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:86,277,678...86,286,954
Ensembl chr 1:86,277,678...86,286,954
|
|
G |
Gfra3 |
GDNF family receptor alpha 3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of GFRA3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr18:26,297,828...26,326,105
Ensembl chr18:26,297,829...26,326,105
|
|
G |
Gfra4 |
GDNF family receptor alpha 4 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of GFRA4 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 3:118,254,937...118,262,252
Ensembl chr 3:118,255,402...118,258,329
|
|
G |
Ggta1 |
glycoprotein alpha-galactosyltransferase 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of GGTA1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 3:18,732,985...18,824,916
Ensembl chr 3:18,732,991...18,809,908
|
|
G |
Gng2 |
G protein subunit gamma 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of GNG2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr15:4,316,038...4,416,918
Ensembl chr15:4,316,059...4,417,183
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with Diethylhexyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate] results in increased expression of GPX1 mRNA; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of GPX1 mRNA |
CTD |
PMID:28013214 PMID:37021957 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of GSR mRNA |
CTD |
PMID:28013214 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Gsta3 |
glutathione S-transferase alpha 3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of GSTA3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 9:23,658,574...23,684,240
Ensembl chr 9:23,658,574...23,684,240
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
decreases expression |
EXP |
diisobutyl phthalate results in decreased expression of HMGCR mRNA |
CTD |
PMID:28655647 PMID:33983380 |
|
NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
|
|
G |
Hmgcs1 |
3-hydroxy-3-methylglutaryl-CoA synthase 1 |
decreases expression |
EXP |
diisobutyl phthalate results in decreased expression of HMGCS1 mRNA |
CTD |
PMID:28655647 PMID:33983380 |
|
NCBI chr 2:51,649,368...51,667,100
Ensembl chr 2:51,649,497...51,667,100
|
|
G |
Hoxb8 |
homeo box B8 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of HOXB8 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr10:81,248,313...81,251,261
Ensembl chr10:81,248,887...81,250,638
|
|
G |
Hoxd3 |
homeo box D3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of HOXD3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 3:59,638,708...59,650,282
Ensembl chr 3:59,638,708...59,650,282
|
|
G |
Hsd17b3 |
hydroxysteroid (17-beta) dehydrogenase 3 |
increases expression |
EXP |
diisobutyl phthalate results in increased expression of HSD17B3 mRNA |
CTD |
PMID:28655647 |
|
NCBI chr17:1,027,229...1,058,554
Ensembl chr17:1,027,229...1,058,554
|
|
G |
Hsd3b1 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 |
multiple interactions |
ISO EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of HSD3B1 mRNA [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of HSD3B1 mRNA |
CTD |
PMID:28013214 PMID:35762964 |
|
NCBI chr 2:186,169,864...186,175,984
Ensembl chr 2:186,169,863...186,175,999
|
|
G |
Hsd3b2 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of HSD3B2 mRNA] |
CTD |
PMID:37552060 |
|
NCBI chr 2:186,095,897...186,105,354
Ensembl chr 2:186,095,897...186,101,852
|
|
G |
Hsd3b3 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 3 |
multiple interactions decreases expression |
EXP |
[diethyl phthalate co-treated with diisobutyl phthalate] results in decreased expression of HSD3B3 mRNA diisobutyl phthalate results in decreased expression of HSD3B3 mRNA |
CTD |
PMID:33983380 |
|
NCBI chr 2:186,138,044...186,144,024
Ensembl chr 2:186,138,044...186,144,033
|
|
G |
Hspa12a |
heat shock protein family A (Hsp70) member 12A |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of HSPA12A mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:257,935,642...258,096,602
Ensembl chr 1:257,935,644...258,096,846
|
|
G |
Ido2 |
indoleamine 2,3-dioxygenase 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of IDO2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr16:67,459,158...67,498,052
Ensembl chr16:67,459,190...67,496,324
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with diisononyl phthalate co-treated with butylbenzyl phthalate] affects the expression of and affects the secretion of IFNG protein |
CTD |
PMID:38954831 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Igfbp2 |
insulin-like growth factor binding protein 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with diisononyl phthalate co-treated with butylbenzyl phthalate] results in decreased secretion of IGFBP2 protein |
CTD |
PMID:38954831 |
|
NCBI chr 9:74,415,574...74,442,945
Ensembl chr 9:74,415,546...74,442,937
|
|
G |
Igfbp6 |
insulin-like growth factor binding protein 6 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with diisononyl phthalate co-treated with butylbenzyl phthalate] results in decreased secretion of IGFBP6 protein |
CTD |
PMID:38954831 |
|
NCBI chr 7:133,276,309...133,280,944
Ensembl chr 7:133,276,234...133,280,966
|
|
G |
Il13 |
interleukin 13 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with diisononyl phthalate co-treated with butylbenzyl phthalate] affects the expression of and affects the secretion of IL13 protein |
CTD |
PMID:38954831 |
|
NCBI chr10:37,790,130...37,792,687
Ensembl chr10:37,790,130...37,792,737
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with Diethylhexyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate] results in increased expression of IL1B mRNA |
CTD |
PMID:37021957 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of IL6 mRNA] |
CTD |
PMID:33316053 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Inha |
inhibin subunit alpha |
decreases expression |
EXP |
diisobutyl phthalate results in decreased expression of INHA mRNA |
CTD |
PMID:33983380 |
|
NCBI chr 9:76,994,465...76,997,366
Ensembl chr 9:76,993,589...76,997,248
|
|
G |
Insig1 |
insulin induced gene 1 |
decreases expression |
EXP |
diisobutyl phthalate results in decreased expression of INSIG1 mRNA |
CTD |
PMID:33983380 |
|
NCBI chr 4:7,315,494...7,323,972
Ensembl chr 4:7,315,495...7,323,952
|
|
G |
Insl3 |
insulin-like 3 |
decreases expression multiple interactions |
EXP |
diisobutyl phthalate results in decreased expression of INSL3 mRNA [diethyl phthalate co-treated with diisobutyl phthalate] results in decreased expression of INSL3 mRNA; [diisobutyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate] results in decreased expression of INSL3 mRNA |
CTD |
PMID:22112501 PMID:33983380 PMID:37788136 |
|
NCBI chr16:18,398,682...18,400,566
Ensembl chr16:18,384,829...18,400,560
|
|
G |
Kif5a |
kinesin family member 5A |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of KIF5A protein; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of KIF5A mRNA |
CTD |
PMID:37690569 |
|
NCBI chr 7:63,051,894...63,089,024
Ensembl chr 7:63,049,424...63,092,858
|
|
G |
Kif5c |
kinesin family member 5C |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of KIF5C mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 3:34,032,082...34,185,597
Ensembl chr 3:34,032,105...34,182,413
|
|
G |
L1cam |
L1 cell adhesion molecule |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of L1CAM mRNA; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of L1CAM protein |
CTD |
PMID:31199487 PMID:37690569 |
|
NCBI chr X:151,597,270...151,623,776
Ensembl chr X:151,597,277...151,623,857
|
|
G |
Lcn2 |
lipocalin 2 |
multiple interactions |
EXP ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of LCN2 mRNA [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with diisononyl phthalate co-treated with butylbenzyl phthalate] results in decreased secretion of LCN2 protein |
CTD |
PMID:31199487 PMID:38954831 |
|
NCBI chr 3:15,680,688...15,684,033
Ensembl chr 3:15,680,687...15,684,095
|
|
G |
Ldlr |
low density lipoprotein receptor |
decreases expression |
EXP |
diisobutyl phthalate results in decreased expression of LDLR mRNA |
CTD |
PMID:33983380 |
|
NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580
|
|
G |
Lep |
leptin |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with diisononyl phthalate co-treated with butylbenzyl phthalate] results in decreased secretion of LEP protein |
CTD |
PMID:38954831 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Lhb |
luteinizing hormone subunit beta |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisobutyl phthalate co-treated with diisononyl phthalate] results in decreased secretion of LHB protein |
CTD |
PMID:37839492 |
|
NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972 Ensembl chr 1:95,900,984...95,901,972
|
|
G |
Lhcgr |
luteinizing hormone/choriogonadotropin receptor |
multiple interactions |
EXP |
[diethyl phthalate co-treated with diisobutyl phthalate] results in decreased expression of LHCGR mRNA |
CTD |
PMID:33983380 |
|
NCBI chr 6:5,661,871...5,728,109
Ensembl chr 6:5,661,871...5,724,521
|
|
G |
Lonrf2 |
LON peptidase N-terminal domain and ring finger 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of LONRF2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 9:41,033,125...41,070,551
Ensembl chr 9:41,034,628...41,070,649
|
|
G |
Lpl |
lipoprotein lipase |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of LPL mRNA |
CTD |
PMID:30768133 |
|
NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249
|
|
G |
Lrrc4b |
leucine rich repeat containing 4B |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of LRRC4B mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:94,922,034...94,956,309
Ensembl chr 1:94,935,603...94,956,263
|
|
G |
Lynx1 |
Ly6/neurotoxin 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of LYNX1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 7:106,632,800...106,638,003
Ensembl chr 7:106,632,797...106,638,023
|
|
G |
Map6 |
microtubule-associated protein 6 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of MAP6 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:153,568,020...153,634,415
Ensembl chr 1:153,568,368...153,634,414
|
|
G |
Mapt |
microtubule-associated protein tau |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of MAPT mRNA |
CTD |
PMID:31199487 |
|
NCBI chr10:89,138,644...89,236,137
Ensembl chr10:89,138,627...89,236,129
|
|
G |
Mir141 |
microRNA 141 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of MIR141 |
CTD |
PMID:31199487 |
|
NCBI chr 4:157,523,239...157,523,332
Ensembl chr 4:157,523,239...157,523,332
|
|
G |
Mir184 |
microRNA 184 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of MIR184; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of MIR184 mRNA |
CTD |
PMID:31199487 PMID:35762964 |
|
NCBI chr 8:90,343,134...90,343,210
Ensembl chr 8:90,343,134...90,343,210
|
|
G |
Mllt11 |
MLLT11, transcription factor 7 cofactor |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of MLLT11 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 2:182,795,790...182,804,960
Ensembl chr 2:182,795,790...182,797,199
|
|
G |
Mmp14 |
matrix metallopeptidase 14 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] promotes the reaction [CGA protein results in increased expression of MMP14 mRNA] |
CTD |
PMID:33316053 |
|
NCBI chr15:27,887,795...27,897,020
Ensembl chr15:27,887,727...27,899,864
|
|
G |
Mmp16 |
matrix metallopeptidase 16 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] promotes the reaction [CGA protein results in increased expression of MMP16 mRNA] |
CTD |
PMID:33316053 |
|
NCBI chr 5:31,312,280...31,556,276
Ensembl chr 5:31,312,280...31,548,388
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of MMP9 mRNA] |
CTD |
PMID:33316053 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mvd |
mevalonate diphosphate decarboxylase |
decreases expression |
EXP |
diisobutyl phthalate results in decreased expression of MVD mRNA |
CTD |
PMID:33983380 |
|
NCBI chr19:50,496,366...50,506,429
Ensembl chr19:50,496,367...50,507,971
|
|
G |
Ncs1 |
neuronal calcium sensor 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of NCS1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 3:14,523,220...14,568,829
Ensembl chr 3:14,523,220...14,568,829
|
|
G |
Ndrg4 |
NDRG family member 4 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of NDRG4 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr19:9,351,408...9,387,398
Ensembl chr19:9,351,404...9,386,914
|
|
G |
Nefh |
neurofilament heavy chain |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of NEFH mRNA |
CTD |
PMID:31199487 |
|
NCBI chr14:79,830,362...79,840,347
Ensembl chr14:79,830,362...79,840,351
|
|
G |
Nefl |
neurofilament light chain |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of NEFL mRNA |
CTD |
PMID:31199487 |
|
NCBI chr15:42,301,920...42,305,793
Ensembl chr15:42,301,916...42,305,793
|
|
G |
Nell1 |
neural EGFL like 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of NELL1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:99,709,305...100,573,872
Ensembl chr 1:99,709,793...100,573,860
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with Diethylhexyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate] results in increased expression of NFE2L2 mRNA |
CTD |
PMID:37021957 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Ngfr |
nerve growth factor receptor |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of NGFR mRNA |
CTD |
PMID:31199487 |
|
NCBI chr10:80,515,287...80,533,518
Ensembl chr10:80,515,299...80,533,518
|
|
G |
Nr0b1 |
nuclear receptor subfamily 0, group B, member 1 |
decreases expression |
EXP |
diisobutyl phthalate results in decreased expression of NR0B1 mRNA |
CTD |
PMID:33983380 |
|
NCBI chr X:50,756,886...50,761,014
Ensembl chr X:50,756,886...50,761,011
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
increases activity |
ISO |
diisobutyl phthalate results in increased activity of NR1I2 protein alternative form |
CTD |
PMID:21227907 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
multiple interactions affects binding increases activity |
ISO |
[diisobutyl phthalate co-treated with Androstanols] results in increased activity of NR1I3 protein alternative form diisobutyl phthalate binds to NR1I3 protein diisobutyl phthalate results in increased activity of NR1I3 protein alternative form |
CTD |
PMID:21227907 PMID:25938866 |
|
NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906
|
|
G |
Nrxn2 |
neurexin 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of NRXN2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:203,726,420...203,842,301
Ensembl chr 1:203,735,753...203,842,297
|
|
G |
Nsdhl |
NAD(P) dependent steroid dehydrogenase-like |
decreases expression |
EXP |
diisobutyl phthalate results in decreased expression of NSDHL mRNA |
CTD |
PMID:33983380 |
|
NCBI chr X:150,775,034...150,807,161
Ensembl chr X:150,775,080...150,807,142
|
|
G |
Nsg1 |
neuronal vesicle trafficking associated 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of NSG1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr14:72,648,771...72,670,521
Ensembl chr14:72,648,741...72,670,514
|
|
G |
Nsg2 |
neuronal vesicle trafficking associated 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of NSG2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr10:15,601,594...15,661,441
Ensembl chr10:15,601,596...15,661,441
|
|
G |
Olfm1 |
olfactomedin 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of OLFM1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 3:11,520,522...11,558,240
Ensembl chr 3:11,520,729...11,558,239
|
|
G |
Pcp4 |
Purkinje cell protein 4 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of PCP4 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr11:35,759,711...35,861,725
Ensembl chr11:35,800,713...35,861,725
|
|
G |
Pcsk9 |
proprotein convertase subtilisin/kexin type 9 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with diisononyl phthalate co-treated with butylbenzyl phthalate] results in decreased secretion of PCSK9 protein |
CTD |
PMID:38954831 |
|
NCBI chr 5:121,211,278...121,233,688
Ensembl chr 5:121,211,278...121,233,688
|
|
G |
Pdgfb |
platelet derived growth factor subunit B |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with diisononyl phthalate co-treated with butylbenzyl phthalate] results in increased secretion of PDGFB protein |
CTD |
PMID:38954831 |
|
NCBI chr 7:111,539,444...111,557,984
Ensembl chr 7:111,540,345...111,557,984
|
|
G |
Pgr |
progesterone receptor |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of PGR mRNA] [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of PGR mRNA]; Cyclic AMP inhibits the reaction [[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of PGR mRNA]] |
CTD |
PMID:33316053 PMID:37552060 |
|
NCBI chr 8:6,072,673...6,131,552
Ensembl chr 8:6,072,673...6,131,344
|
|
G |
Plat |
plasminogen activator, tissue type |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of PLAT mRNA] |
CTD |
PMID:33316053 |
|
NCBI chr16:69,240,582...69,265,177
Ensembl chr16:69,240,585...69,268,223
|
|
G |
Plin1 |
perilipin 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with Diethylhexyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate] results in increased expression of PLIN1 mRNA |
CTD |
PMID:37021957 |
|
NCBI chr 1:133,664,294...133,676,854
Ensembl chr 1:133,664,892...133,676,828
|
|
G |
Plppr3 |
phospholipid phosphatase related 3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of PLPPR3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 7:9,831,162...9,842,434
Ensembl chr 7:9,831,162...9,845,296
|
|
G |
Pls1 |
plastin 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of PLS1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 8:96,316,703...96,426,592
Ensembl chr 8:96,317,849...96,385,195
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of PPARA mRNA |
CTD |
PMID:28013214 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions increases expression increases activity |
ISO |
diisobutyl phthalate binds to and results in increased activity of PPARG protein diisobutyl phthalate results in increased expression of PPARG protein diisobutyl phthalate results in increased activity of PPARG protein |
CTD |
PMID:24155963 PMID:26172262 PMID:27633901 PMID:29061543 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with Diethylhexyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate] results in decreased expression of PPARGC1A mRNA |
CTD |
PMID:37021957 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Ppp2r2b |
protein phosphatase 2, regulatory subunit B, beta |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of PPP2R2B mRNA |
CTD |
PMID:31199487 |
|
NCBI chr18:34,653,716...35,080,889
Ensembl chr18:34,653,721...35,081,025
|
|
G |
Prima1 |
proline rich membrane anchor 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of PRIMA1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 6:122,338,365...122,390,955
Ensembl chr 6:122,338,370...122,389,921
|
|
G |
Prph |
peripherin |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of PRPH mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 7:130,218,149...130,222,136
Ensembl chr 7:130,218,357...130,222,136
|
|
G |
Ptges |
prostaglandin E synthase |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of PTGES mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 3:14,177,892...14,189,236
|
|
G |
Ptgr1 |
prostaglandin reductase 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of PTGR1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 5:73,784,000...73,802,624
Ensembl chr 5:73,784,009...73,802,666
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of PTGS2 mRNA] |
CTD |
PMID:33316053 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Ptprn |
protein tyrosine phosphatase, receptor type, N |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of PTPRN mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 9:76,741,010...76,756,704
Ensembl chr 9:76,741,016...76,756,190
|
|
G |
Ptx3 |
pentraxin 3 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the reaction [CGA protein results in increased expression of PTX3 mRNA] [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with diisononyl phthalate co-treated with butylbenzyl phthalate] results in decreased secretion of PTX3 protein |
CTD |
PMID:37552060 PMID:38954831 |
|
NCBI chr 2:150,487,513...150,493,323
Ensembl chr 2:150,487,513...150,493,323
|
|
G |
Qsox1 |
quiescin sulfhydryl oxidase 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of QSOX1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr13:67,949,780...67,987,434
Ensembl chr13:67,949,780...67,987,459
|
|
G |
Rab3b |
RAB3B, member RAS oncogene family |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of RAB3B mRNA; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of RAB3B protein |
CTD |
PMID:31199487 PMID:37690569 |
|
NCBI chr 5:123,629,562...123,697,410
Ensembl chr 5:123,644,423...123,697,401
|
|
G |
Rab6b |
RAB6B, member RAS oncogene family |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of RAB6B mRNA; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of RAB6B protein |
CTD |
PMID:31199487 PMID:37690569 |
|
NCBI chr 8:103,695,328...103,764,023
Ensembl chr 8:103,695,631...103,805,732
|
|
G |
Rarres2 |
retinoic acid receptor responder 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with diisononyl phthalate co-treated with butylbenzyl phthalate] results in decreased secretion of RARRES2 protein |
CTD |
PMID:38954831 |
|
NCBI chr 4:77,522,549...77,525,733
Ensembl chr 4:77,522,535...77,525,556
|
|
G |
Rassf4 |
Ras association domain family member 4 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of RASSF4 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 4:149,897,525...149,932,658
Ensembl chr 4:149,897,543...149,932,411
|
|
G |
Rbp4 |
retinol binding protein 4 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with diisononyl phthalate co-treated with butylbenzyl phthalate] results in decreased secretion of RBP4 protein |
CTD |
PMID:38954831 |
|
NCBI chr 1:235,893,917...235,901,315
Ensembl chr 1:235,893,917...235,901,399
|
|
G |
Resp18 |
regulated endocrine-specific protein 18 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of RESP18 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 9:76,765,179...76,771,824
Ensembl chr 9:76,764,590...76,778,722
|
|
G |
Rgs2 |
regulator of G-protein signaling 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of RGS2 mRNA] |
CTD |
PMID:37552060 |
|
NCBI chr13:55,799,749...55,802,354
Ensembl chr13:55,798,829...55,802,385
|
|
G |
Rnf183 |
ring finger protein 183 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of RNF183 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 5:75,877,111...75,886,253
Ensembl chr 5:75,876,003...75,886,191
|
|
G |
Rtn1 |
reticulon 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of RTN1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 6:90,763,212...90,983,436
Ensembl chr 6:90,763,216...90,983,436
|
|
G |
Rtn4r |
reticulon 4 receptor |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of RTN4R mRNA |
CTD |
PMID:31199487 |
|
NCBI chr11:82,844,309...82,869,251
Ensembl chr11:82,844,309...82,869,466
|
|
G |
Rxrg |
retinoid X receptor gamma |
decreases expression |
EXP |
diisobutyl phthalate results in decreased expression of RXRG mRNA |
CTD |
PMID:22112501 |
|
NCBI chr13:79,743,430...79,785,173
Ensembl chr13:79,743,563...79,785,167
|
|
G |
Scarb1 |
scavenger receptor class B, member 1 |
decreases expression multiple interactions |
EXP |
diisobutyl phthalate results in decreased expression of SCARB1 mRNA [diethyl phthalate co-treated with diisobutyl phthalate] results in decreased expression of SCARB1 mRNA |
CTD |
PMID:22112501 PMID:28655647 PMID:33983380 |
|
NCBI chr12:31,296,143...31,362,649
Ensembl chr12:31,296,156...31,362,647
|
|
G |
Scg3 |
secretogranin III |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SCG3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 8:76,399,777...76,442,015
Ensembl chr 8:76,399,777...76,442,015
|
|
G |
Scn3b |
sodium voltage-gated channel beta subunit 3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SCN3B mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 8:40,630,372...40,652,869
Ensembl chr 8:40,630,455...40,652,868
|
|
G |
Scrn1 |
secernin 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SCRN1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 4:83,632,125...83,694,225
Ensembl chr 4:83,632,131...83,693,852
|
|
G |
Serpinb2 |
serpin family B member 2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of SERPINB2 mRNA] |
CTD |
PMID:33316053 |
|
NCBI chr13:23,537,312...23,551,823
Ensembl chr13:23,541,400...23,550,408
|
|
G |
Serpine1 |
serpin family E member 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of SERPINE1 mRNA] |
CTD |
PMID:33316053 |
|
NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657
|
|
G |
Serpinf1 |
serpin family F member 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with diisononyl phthalate co-treated with butylbenzyl phthalate] results in decreased secretion of SERPINF1 protein |
CTD |
PMID:38954831 |
|
NCBI chr10:60,250,198...60,262,593
Ensembl chr10:60,249,708...60,262,646
|
|
G |
Sh3gl3 |
SH3 domain containing GRB2 like 3, endophilin A3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SH3GL3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:136,124,500...136,255,669
Ensembl chr 1:136,124,499...136,255,584
|
|
G |
Sh3tc2 |
SH3 domain and tetratricopeptide repeats 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SH3TC2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr18:55,416,383...55,477,419
Ensembl chr18:55,416,413...55,483,083
|
|
G |
Shc2 |
SHC adaptor protein 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SHC2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 7:10,066,705...10,088,926
Ensembl chr 7:10,066,705...10,088,926
|
|
G |
Slc13a2 |
solute carrier family 13 member 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SLC13A2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr10:63,291,813...63,319,127
Ensembl chr10:63,291,815...63,319,127
|
|
G |
Slc29a4 |
solute carrier family 29 member 4 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SLC29A4 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr12:11,853,540...11,884,660
Ensembl chr12:11,853,540...11,874,834
|
|
G |
Slc5a7 |
solute carrier family 5 member 7 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SLC5A7 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 9:7,595,440...7,626,258
Ensembl chr 9:7,595,444...7,626,258
|
|
G |
Slco2a1 |
solute carrier organic anion transporter family, member 2a1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] promotes the reaction [CGA protein results in increased expression of SLCO2A1 mRNA] |
CTD |
PMID:33316053 |
|
NCBI chr 8:103,588,916...103,672,546
Ensembl chr 8:103,588,916...103,672,546
|
|
G |
Smim24 |
small integral membrane protein 24 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SMIM24 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 7:8,313,369...8,316,498
|
|
G |
Snhg11 |
small nucleolar RNA host gene 11 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SNHG11 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 3:147,031,367...147,037,043
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SOD1 mRNA |
CTD |
PMID:28013214 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Sox9 |
SRY-box transcription factor 9 |
increases expression |
EXP |
diisobutyl phthalate results in increased expression of SOX9 mRNA |
CTD |
PMID:22112501 |
|
NCBI chr10:97,806,485...97,811,994
Ensembl chr10:97,806,485...97,811,994
|
|
G |
Star |
steroidogenic acute regulatory protein |
decreases expression multiple interactions |
EXP ISO |
diisobutyl phthalate results in decreased expression of STAR mRNA; diisobutyl phthalate results in decreased expression of STAR protein [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of STAR mRNA] [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of STAR mRNA; [diethyl phthalate co-treated with diisobutyl phthalate] results in decreased expression of STAR mRNA; [diisobutyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate] results in decreased expression of STAR mRNA [diethyl phthalate co-treated with Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisobutyl phthalate co-treated with diisononyl phthalate] results in increased expression of STAR mRNA; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of STAR mRNA; [Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diethyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate] results in decreased expression of STAR mRNA; [Diethylhexyl Phthalate co-treated with diethyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate] results in decreased expression of STAR mRNA |
CTD |
PMID:16458459 PMID:21633115 PMID:22112501 PMID:28013214 PMID:28655647 PMID:30802670 PMID:33983380 PMID:34597818 PMID:35762964 PMID:37552060 PMID:37788136 PMID:37839492 More...
|
|
NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672
|
|
G |
Stk32c |
serine/threonine kinase 32C |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of STK32C mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:193,900,718...193,981,723
Ensembl chr 1:193,900,718...193,981,723
|
|
G |
Stmn4 |
stathmin 4 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of STMN4 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr15:40,541,305...40,559,253
Ensembl chr15:40,541,357...40,559,253
|
|
G |
Syt11 |
synaptotagmin 11 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SYT11 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 2:174,206,032...174,232,540
Ensembl chr 2:174,206,191...174,231,964
|
|
G |
Syt5 |
synaptotagmin 5 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SYT5 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:69,277,351...69,285,071
Ensembl chr 1:69,277,351...69,285,067
|
|
G |
Tbx2 |
T-box transcription factor 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TBX2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr10:70,679,670...70,688,868
Ensembl chr10:70,679,518...70,688,529
|
|
G |
Tcf23 |
transcription factor 23 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TCF23 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 6:25,397,889...25,406,639
Ensembl chr 6:25,397,937...25,405,880
|
|
G |
Tcte1 |
t-complex-associated testis expressed 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TCTE1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 9:15,463,573...15,482,258
Ensembl chr 9:15,463,739...15,472,954
|
|
G |
Thrb |
thyroid hormone receptor beta |
multiple interactions |
ISO |
diisobutyl phthalate binds to and results in decreased activity of THRB protein |
CTD |
PMID:27633901 |
|
NCBI chr15:7,685,180...8,031,920
Ensembl chr15:7,685,180...7,882,916
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of TIMP1 mRNA] |
CTD |
PMID:33316053 |
|
NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664
|
|
G |
Tm7sf2 |
transmembrane 7 superfamily member 2 |
decreases expression |
EXP |
diisobutyl phthalate results in decreased expression of TM7SF2 mRNA |
CTD |
PMID:33983380 |
|
NCBI chr 1:203,355,930...203,360,287
Ensembl chr 1:203,355,931...203,360,270
|
|
G |
Tmeff2 |
transmembrane protein with EGF-like and two follistatin-like domains 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TMEFF2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 9:50,445,947...50,733,473
Ensembl chr 9:50,436,079...50,733,475
|
|
G |
Tmem130 |
transmembrane protein 130 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TMEM130 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr12:9,837,055...9,862,843
Ensembl chr12:9,837,055...9,862,840
|
|
G |
Tmem35a |
transmembrane protein 35A |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TMEM35A mRNA |
CTD |
PMID:31199487 |
|
NCBI chr X:97,503,350...97,514,198
Ensembl chr X:97,503,350...97,514,197
|
|
G |
Tmem63c |
transmembrane protein 63c |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TMEM63C mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 6:106,667,389...106,738,778
Ensembl chr 6:106,672,934...106,736,990
|
|
G |
Tnfrsf11b |
TNF receptor superfamily member 11B |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with diisononyl phthalate co-treated with butylbenzyl phthalate] results in decreased secretion of TNFRSF11B protein |
CTD |
PMID:38954831 |
|
NCBI chr 7:85,566,520...85,594,526
Ensembl chr 7:85,566,520...85,594,538
|
|
G |
Trpc6 |
transient receptor potential cation channel, subfamily C, member 6 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TRPC6 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 8:5,759,387...5,864,000
Ensembl chr 8:5,758,935...5,828,092
|
|
G |
Tshb |
thyroid stimulating hormone subunit beta |
multiple interactions |
ISO |
[diisobutyl phthalate results in increased abundance of mono-isobutyl phthalate] which results in decreased secretion of TSHB protein |
CTD |
PMID:29734584 |
|
NCBI chr 2:190,224,676...190,229,559
Ensembl chr 2:190,224,676...190,229,559
|
|
G |
Ttyh1 |
tweety family member 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TTYH1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:70,053,312...70,071,872
Ensembl chr 1:70,053,324...70,071,845
|
|
G |
Tubb2b |
tubulin, beta 2B class IIb |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of TUBB2B protein; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TUBB2B mRNA |
CTD |
PMID:31199487 PMID:37690569 |
|
NCBI chr17:30,747,734...30,750,781
Ensembl chr17:30,747,734...30,750,638
|
|
G |
Tubb3 |
tubulin, beta 3 class III |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of TUBB3 protein; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TUBB3 mRNA |
CTD |
PMID:31199487 PMID:37690569 |
|
NCBI chr19:51,457,187...51,466,243
Ensembl chr19:51,457,184...51,466,243
|
|
G |
Tubb4a |
tubulin, beta 4A class IVa |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of TUBB4A protein; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TUBB4A mRNA |
CTD |
PMID:31199487 PMID:37690569 |
|
NCBI chr 9:1,917,841...1,925,286
Ensembl chr 9:1,917,845...1,925,291
|
|
G |
Ubash3b |
ubiquitin associated and SH3 domain containing, B |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of UBASH3B mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 8:41,385,419...41,532,248
Ensembl chr 8:41,388,341...41,532,201
|
|
G |
Ubxn11 |
UBX domain protein 11 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of UBXN11 mRNA |
CTD |
PMID:31199487 PMID:37690569 |
|
NCBI chr 5:146,329,666...146,353,529
Ensembl chr 5:146,329,842...146,353,526
|
|
G |
Ucp1 |
uncoupling protein 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with Diethylhexyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate] results in decreased expression of UCP1 mRNA |
CTD |
PMID:37021957 |
|
NCBI chr19:24,808,782...24,816,853
Ensembl chr19:24,808,783...24,816,852
|
|
G |
Wnt4 |
Wnt family member 4 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of WNT4 mRNA] |
CTD |
PMID:33316053 |
|
NCBI chr 5:149,513,573...149,535,415
Ensembl chr 5:149,514,018...149,532,859
|
|
G |
Wnt6 |
Wnt family member 6 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of WNT6 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 9:76,329,882...76,343,523
Ensembl chr 9:76,329,882...76,343,523
|
|
G |
Wnt9b |
Wnt family member 9B |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of WNT9B mRNA |
CTD |
PMID:31199487 |
|
NCBI chr10:88,635,330...88,657,035
Ensembl chr10:88,635,331...88,657,035
|
|
G |
Wt1 |
WT1 transcription factor |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of WT1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 3:91,566,540...91,613,653
Ensembl chr 3:91,567,001...91,613,643
|
|
G |
Zcchc12 |
zinc finger CCHC-type containing 12 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ZCCHC12 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr X:115,433,444...115,436,691
Ensembl chr X:115,433,259...115,436,692
|
|
G |
Zfat |
zinc finger and AT hook domain containing |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of ZFAT mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 7:99,886,954...100,054,288
Ensembl chr 7:99,886,954...100,054,274
|
|
G |
Zp2 |
zona pellucida glycoprotein 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ZP2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:174,513,507...174,525,288
Ensembl chr 1:174,513,511...174,525,288
|
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
increases expression |
ISO |
fenpyroximate results in increased expression of ABCA1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170
|
|
G |
Ache |
acetylcholinesterase |
decreases activity |
EXP |
fenpyroximate results in decreased activity of ACHE protein |
CTD |
PMID:35580743 |
|
NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Akr1b1 |
aldo-keto reductase family 1 member B1 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of AKR1B1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 4:62,932,033...62,946,126
Ensembl chr 4:62,932,031...62,946,157
|
|
G |
Akr7a2 |
aldo-keto reductase family 7, member A2 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of AKR7A2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 5:151,552,375...151,560,914
Ensembl chr 5:151,552,343...151,560,909
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of AKT1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Aldh9a1 |
aldehyde dehydrogenase 9 family, member A1 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of ALDH9A1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr13:79,505,738...79,522,539
Ensembl chr13:79,505,695...79,540,568
|
|
G |
Amer1 |
APC membrane recruitment protein 1 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of AMER1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr X:60,300,595...60,316,480
Ensembl chr X:60,295,751...60,316,440
|
|
G |
Ano10 |
anoctamin 10 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of ANO10 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 8:121,841,664...121,960,739
Ensembl chr 8:121,841,665...121,962,670
|
|
G |
Ap3m1 |
adaptor related protein complex 3 subunit mu 1 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of AP3M1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr15:3,246,616...3,264,846
Ensembl chr15:3,246,926...3,264,844
|
|
G |
Apex1 |
apurinic/apyrimidinic endodeoxyribonuclease 1 |
increases expression |
ISO |
fenpyroximate results in increased expression of APEX1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr15:24,144,595...24,146,785
Ensembl chr15:24,144,362...24,146,785
|
|
G |
Arg1 |
arginase 1 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of ARG1 mRNA |
CTD |
PMID:32194361 |
|
NCBI chr 1:20,475,878...20,488,422
Ensembl chr 1:20,475,968...20,488,422
|
|
G |
Arhgap9 |
Rho GTPase activating protein 9 |
increases expression |
ISO |
fenpyroximate results in increased expression of ARHGAP9 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 7:63,148,573...63,157,025
Ensembl chr 7:63,148,900...63,157,524
|
|
G |
Arrdc4 |
arrestin domain containing 4 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of ARRDC4 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:122,369,355...122,383,351
Ensembl chr 1:122,369,360...122,383,290
|
|
G |
Asns |
asparagine synthetase (glutamine-hydrolyzing) |
increases expression |
ISO |
fenpyroximate results in increased expression of ASNS mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 4:35,784,995...35,803,474
Ensembl chr 4:35,785,237...35,803,423
|
|
G |
Ass1 |
argininosuccinate synthase 1 |
increases expression |
ISO |
fenpyroximate results in increased expression of ASS1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 3:14,747,355...14,796,909
Ensembl chr 3:14,747,368...14,796,903
|
|
G |
Atf4 |
activating transcription factor 4 |
increases expression |
ISO |
fenpyroximate results in increased expression of ATF4 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446
|
|
G |
Atf5 |
activating transcription factor 5 |
increases expression |
ISO |
fenpyroximate results in increased expression of ATF5 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:95,295,602...95,299,755
Ensembl chr 1:95,295,610...95,299,707
|
|
G |
Atmin |
ATM interactor |
decreases expression |
ISO |
fenpyroximate results in decreased expression of ATMIN mRNA |
CTD |
PMID:33512557 |
|
NCBI chr19:44,996,506...45,013,606
Ensembl chr19:44,996,356...45,013,605
|
|
G |
Atp5f1b |
ATP synthase F1 subunit beta |
decreases expression |
ISO |
fenpyroximate results in decreased expression of ATP5F1B mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 7:515,454...521,858
Ensembl chr 7:515,460...567,273
|
|
G |
Atp5f1c |
ATP synthase F1 subunit gamma |
decreases expression |
ISO |
fenpyroximate results in decreased expression of ATP5F1C mRNA |
CTD |
PMID:33512557 |
|
NCBI chr17:68,423,927...68,446,169
Ensembl chr17:68,423,909...68,608,367
|
|
G |
Atp6v1b2 |
ATPase H+ transporting V1 subunit B2 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of ATP6V1B2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr16:20,617,515...20,641,651
Ensembl chr16:20,617,518...20,641,745
|
|
G |
Aurka |
aurora kinase A |
increases expression |
ISO |
fenpyroximate results in increased expression of AURKA mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 3:161,128,309...161,144,524
Ensembl chr 3:161,128,313...161,144,390
|
|
G |
B2m |
beta-2 microglobulin |
increases expression |
ISO |
fenpyroximate results in increased expression of B2M mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 3:109,095,740...109,101,764
Ensembl chr 3:109,095,729...109,101,766
|
|
G |
B3galt6 |
Beta-1,3-galactosyltransferase 6 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of B3GALT6 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 5:166,584,202...166,586,338
Ensembl chr 5:166,584,202...166,586,338
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression |
ISO |
fenpyroximate results in increased expression of BAX mRNA |
CTD |
PMID:36933581 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression |
ISO |
fenpyroximate results in decreased expression of BCL2 mRNA |
CTD |
PMID:36933581 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l13 |
Bcl2-like 13 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of BCL2L13 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 4:154,056,116...154,112,890
Ensembl chr 4:154,056,127...154,108,985
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
increases expression |
ISO |
fenpyroximate results in increased expression of BIRC5 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Bmf |
Bcl2 modifying factor |
decreases expression |
ISO |
fenpyroximate results in decreased expression of BMF mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 3:105,499,534...105,520,159
Ensembl chr 3:105,499,538...105,520,145
|
|
G |
Bphl |
biphenyl hydrolase like |
decreases expression |
ISO |
fenpyroximate results in decreased expression of BPHL mRNA |
CTD |
PMID:33512557 |
|
NCBI chr17:30,800,939...30,837,277
Ensembl chr17:30,799,629...30,837,288
|
|
G |
Bzw1 |
basic leucine zipper and W2 domains 1 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of BZW1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 9:59,930,672...59,944,468
Ensembl chr 9:59,930,744...59,944,430
|
|
G |
C2cd5 |
C2 calcium-dependent domain containing 5 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of C2CD5 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 4:175,969,544...176,055,597
Ensembl chr 4:175,969,545...176,055,558
|
|
G |
Canx |
calnexin |
increases expression |
ISO |
fenpyroximate results in increased expression of CANX mRNA |
CTD |
PMID:33512557 |
|
NCBI chr10:34,623,865...34,656,866
Ensembl chr10:34,625,191...34,656,821
|
|
G |
Cars1 |
cysteinyl-tRNA synthetase 1 |
increases expression |
ISO |
fenpyroximate results in increased expression of CARS1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:198,753,689...198,796,016
Ensembl chr 1:198,753,691...198,795,941
|
|
G |
Casp3 |
caspase 3 |
increases activity multiple interactions |
ISO |
fenpyroximate results in increased activity of CASP3 protein Acetylcysteine inhibits the reaction [fenpyroximate results in increased activity of CASP3 protein] |
CTD |
PMID:35580743 PMID:36933581 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
increases activity |
ISO |
fenpyroximate results in increased activity of CASP9 protein |
CTD |
PMID:36933581 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
increases activity affects activity |
ISO EXP |
fenpyroximate results in increased activity of CAT protein fenpyroximate affects the activity of CAT protein |
CTD |
PMID:35580743 PMID:36933581 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cbr1 |
carbonyl reductase 1 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of CBR1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr11:32,860,571...32,862,981
Ensembl chr11:32,908,950...32,911,393 Ensembl chr11:32,908,950...32,911,393 Ensembl chr11:32,908,950...32,911,393
|
|
G |
Cbx4 |
chromobox 4 |
increases expression |
ISO |
fenpyroximate results in increased expression of CBX4 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr10:104,337,140...104,343,210
Ensembl chr10:104,336,876...104,356,706
|
|
G |
Ccnb1 |
cyclin B1 |
increases expression |
ISO |
fenpyroximate results in increased expression of CCNB1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
|
|
G |
Ccnb2 |
cyclin B2 |
increases expression |
ISO |
fenpyroximate results in increased expression of CCNB2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 8:71,087,594...71,100,794
Ensembl chr 8:71,087,595...71,100,874
|
|
G |
Cd24 |
CD24 molecule |
decreases expression |
ISO |
fenpyroximate results in decreased expression of CD24 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr20:47,074,353...47,079,662
Ensembl chr20:47,073,512...47,079,662
|
|
G |
Cdh10 |
cadherin 10 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of CDH10 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 2:68,628,623...68,850,995
Ensembl chr 2:68,628,780...68,850,995
|
|
G |
Cdh2 |
cadherin 2 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of CDH2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr18:7,776,704...7,990,934
Ensembl chr18:7,776,704...7,990,167
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
increases expression |
ISO |
fenpyroximate results in increased expression of CDK1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
|
|
G |
Cdk5r1 |
cyclin-dependent kinase 5 regulatory subunit 1 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of CDK5R1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr10:65,484,266...65,485,467
Ensembl chr10:65,483,941...65,488,456
|
|
G |
Cdk6 |
cyclin-dependent kinase 6 |
increases expression |
ISO |
fenpyroximate results in increased expression of CDK6 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 4:30,637,650...30,829,688
Ensembl chr 4:30,646,460...30,829,634
|
|
G |
Cdkn3 |
cyclin-dependent kinase inhibitor 3 |
increases expression |
ISO |
fenpyroximate results in increased expression of CDKN3 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr15:20,022,522...20,033,948
Ensembl chr15:20,022,664...20,033,945
|
|
G |
Cebpb |
CCAAT/enhancer binding protein beta |
increases expression |
ISO |
fenpyroximate results in increased expression of CEBPB mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473
|
|
G |
Cel |
carboxyl ester lipase |
decreases expression |
ISO |
fenpyroximate results in decreased expression of CEL mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 3:11,883,532...11,891,035
Ensembl chr 3:11,883,532...11,891,035
|
|
G |
Cfl2 |
cofilin 2 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of CFL2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 6:72,355,664...72,359,709
Ensembl chr 6:72,355,664...72,359,674
|
|
G |
Chac1 |
ChaC glutathione-specific gamma-glutamylcyclotransferase 1 |
increases expression |
ISO |
fenpyroximate results in increased expression of CHAC1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 3:106,342,302...106,345,526
Ensembl chr 3:106,342,302...106,345,526
|
|
G |
Chek1 |
checkpoint kinase 1 |
increases expression |
ISO |
fenpyroximate results in increased expression of CHEK1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 8:36,420,565...36,443,477
Ensembl chr 8:36,420,569...36,441,009
|
|
G |
Chka |
choline kinase alpha |
increases expression |
ISO |
fenpyroximate results in increased expression of CHKA mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:201,076,804...201,125,517
Ensembl chr 1:201,076,860...201,125,516
|
|
G |
Cks1b |
CDC28 protein kinase regulatory subunit 1B |
increases expression |
ISO |
fenpyroximate results in increased expression of CKS1B mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 2:174,833,025...174,837,614
Ensembl chr 2:174,833,050...174,837,636
|
|
G |
Cks2 |
CDC28 protein kinase regulatory subunit 2 |
increases expression |
ISO |
fenpyroximate results in increased expression of CKS2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr17:13,570,611...13,575,770
|
|
G |
Clic4 |
chloride intracellular channel 4 |
increases expression |
ISO |
fenpyroximate results in increased expression of CLIC4 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 5:147,453,702...147,513,455
Ensembl chr 5:147,453,712...147,513,452
|
|
G |
Cnpy3 |
canopy FGF signaling regulator 3 |
increases expression |
ISO |
fenpyroximate results in increased expression of CNPY3 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 9:14,233,478...14,247,847
Ensembl chr 9:14,233,428...14,247,831
|
|
G |
Cntn1 |
contactin 1 |
increases expression |
ISO |
fenpyroximate results in increased expression of CNTN1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 7:123,263,146...123,560,896
Ensembl chr 7:123,372,792...123,558,541
|
|
G |
Coa6 |
cytochrome c oxidase assembly factor 6 |
increases expression |
ISO |
fenpyroximate results in increased expression of COA6 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr19:54,395,746...54,398,348
Ensembl chr19:54,395,742...54,399,407
|
|
G |
Col16a1 |
collagen type XVI alpha 1 chain |
increases expression |
ISO |
fenpyroximate results in increased expression of COL16A1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 5:142,388,376...142,442,825
Ensembl chr 5:142,388,426...142,442,825
|
|
G |
Cops5 |
COP9 signalosome subunit 5 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of COPS5 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 5:9,192,233...9,210,498
Ensembl chr 5:9,192,100...9,210,731
|
|
G |
Crebrf |
CREB3 regulatory factor |
increases expression |
ISO |
fenpyroximate results in increased expression of CREBRF mRNA |
CTD |
PMID:33512557 |
|
NCBI chr10:16,399,170...16,479,650
Ensembl chr10:16,404,596...16,461,999
|
|
G |
Creg1 |
cellular repressor of E1A-stimulated genes 1 |
increases expression |
ISO |
fenpyroximate results in increased expression of CREG1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr13:78,019,814...78,032,310
Ensembl chr13:78,019,843...78,032,308
|
|
G |
Creld2 |
cysteine-rich with EGF-like domains 2 |
increases expression |
ISO |
fenpyroximate results in increased expression of CRELD2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 7:119,909,626...119,916,556
Ensembl chr 7:119,909,633...119,916,543
|
|
G |
Crtap |
cartilage associated protein |
increases expression |
ISO |
fenpyroximate results in increased expression of CRTAP mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 8:114,047,929...114,067,636
Ensembl chr 8:114,047,933...114,067,631
|
|
G |
Ctnnal1 |
catenin alpha-like 1 |
increases expression |
ISO |
fenpyroximate results in increased expression of CTNNAL1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 5:71,514,340...71,569,431
Ensembl chr 5:71,514,340...71,569,431
|
|
G |
Ctnnd1 |
catenin delta 1 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of CTNND1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 3:69,683,328...69,734,550
Ensembl chr 3:69,683,313...69,734,516
|
|
G |
Ctps1 |
CTP synthase 1 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of CTPS1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 5:134,125,022...134,154,155
Ensembl chr 5:134,125,025...134,154,180
|
|
G |
Cttn |
cortactin |
decreases expression |
ISO |
fenpyroximate results in decreased expression of CTTN mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:199,599,710...199,635,254
Ensembl chr 1:199,599,710...199,635,164
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases expression |
ISO |
fenpyroximate results in increased expression of CYP1A1 mRNA |
CTD |
PMID:32194361 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp2c6 |
cytochrome P450, family 2, subfamily C, polypeptide 6 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of CYP2C19 protein |
CTD |
PMID:32194361 |
|
NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
increases expression |
ISO |
fenpyroximate results in increased expression of CYP3A5 mRNA |
CTD |
PMID:34642769 |
|
NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422
|
|
G |
Cyp7a1 |
cytochrome P450 family 7 subfamily A member 1 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of CYP7A1 mRNA; fenpyroximate results in decreased expression of CYP7A1 protein |
CTD |
PMID:32194361 |
|
NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688
|
|
G |
Daam1 |
dishevelled associated activator of morphogenesis 1 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of DAAM1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 6:90,389,544...90,550,114
Ensembl chr 6:90,389,688...90,550,114
|
|
G |
Daxx |
death-domain associated protein |
decreases expression |
ISO |
fenpyroximate results in decreased expression of DAXX mRNA |
CTD |
PMID:33512557 |
|
NCBI chr20:4,970,090...4,976,145
Ensembl chr20:4,970,092...4,975,843
|
|
G |
Dck |
deoxycytidine kinase |
decreases expression |
ISO |
fenpyroximate results in decreased expression of DCK mRNA |
CTD |
PMID:33512557 |
|
NCBI chr14:19,305,218...19,326,247
Ensembl chr14:19,305,218...19,326,247
|
|
G |
Ddc |
dopa decarboxylase |
decreases expression |
ISO |
fenpyroximate results in decreased expression of DDC mRNA |
CTD |
PMID:34642769 |
|
NCBI chr14:86,378,685...86,469,189
Ensembl chr14:86,378,685...86,469,208
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression |
ISO |
fenpyroximate results in increased expression of DDIT3 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Depdc1b |
DEP domain containing 1B |
increases expression |
ISO |
fenpyroximate results in increased expression of DEPDC1B mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 2:39,891,163...39,963,779
Ensembl chr 2:39,891,481...39,963,779
|
|
G |
Dffb |
DNA fragmentation factor subunit beta |
decreases expression |
ISO |
fenpyroximate results in decreased expression of DFFB mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 5:164,522,446...164,534,733
Ensembl chr 5:164,522,463...164,534,628
|
|
G |
Dlgap5 |
DLG associated protein 5 |
increases expression |
ISO |
fenpyroximate results in increased expression of DLGAP5 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr15:20,633,964...20,664,569
Ensembl chr15:20,633,966...20,664,518
|
|
G |
Dnajb14 |
DnaJ heat shock protein family (Hsp40) member B14 |
increases expression |
ISO |
fenpyroximate results in increased expression of DNAJB14 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 2:226,358,988...226,409,461
Ensembl chr 2:226,358,996...226,402,490
|
|
G |
Dnttip2 |
deoxynucleotidyltransferase, terminal, interacting protein 2 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of DNTTIP2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 2:210,374,321...210,386,366
Ensembl chr 2:210,374,289...210,385,581
|
|
G |
Drd2 |
dopamine receptor D2 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of DRD2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 8:49,708,927...49,772,876
Ensembl chr 8:49,708,927...49,772,875
|
|
G |
Dusp4 |
dual specificity phosphatase 4 |
increases expression |
ISO |
fenpyroximate results in increased expression of DUSP4 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr16:57,376,659...57,398,161
Ensembl chr16:57,377,229...57,398,138
|
|
G |
Eef1g |
eukaryotic translation elongation factor 1 gamma |
decreases expression |
ISO |
fenpyroximate results in decreased expression of EEF1G mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:205,860,713...205,871,319
Ensembl chr 1:205,860,698...205,872,382
|
|
G |
Egr1 |
early growth response 1 |
increases expression |
ISO |
fenpyroximate results in increased expression of EGR1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Eif2s2 |
eukaryotic translation initiation factor 2 subunit beta |
increases expression |
ISO |
fenpyroximate results in increased expression of EIF2S2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 3:143,374,652...143,395,460
Ensembl chr 3:143,373,686...143,395,432
|
|
G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
increases expression |
ISO |
fenpyroximate results in increased expression of EIF4EBP1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984
|
|
G |
Elmod1 |
ELMO domain containing 1 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of ELMOD1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 8:54,298,363...54,355,348
Ensembl chr 8:54,298,363...54,355,140
|
|
G |
Ep300 |
E1A binding protein p300 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of EP300 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 7:113,108,476...113,178,529
Ensembl chr 7:113,106,247...113,136,088 Ensembl chr 7:113,106,247...113,136,088
|
|
G |
Ephb2 |
Eph receptor B2 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of EPHB2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 5:148,889,574...149,077,027
Ensembl chr 5:148,897,246...149,077,059
|
|
G |
Ero1a |
endoplasmic reticulum oxidoreductase 1 alpha |
increases expression |
ISO |
fenpyroximate results in increased expression of ERO1A mRNA |
CTD |
PMID:33512557 |
|
NCBI chr15:18,495,037...18,530,440
Ensembl chr15:18,492,945...18,530,478
|
|
G |
Ero1b |
endoplasmic reticulum oxidoreductase 1 beta |
increases expression |
ISO |
fenpyroximate results in increased expression of ERO1B mRNA |
CTD |
PMID:33512557 |
|
NCBI chr17:85,861,086...86,003,244
Ensembl chr17:85,929,618...86,003,398
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions |
ISO |
fenpyroximate inhibits the reaction [Estradiol results in increased activity of ESR2 protein] |
CTD |
PMID:30818834 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Esrra |
estrogen related receptor, alpha |
multiple interactions |
ISO |
fenpyroximate inhibits the reaction [PPARGC1A protein results in increased activity of ESRRA protein]; fenpyroximate inhibits the reaction [XCT790 results in decreased activity of ESRRA protein] |
CTD |
PMID:30818834 |
|
NCBI chr 1:204,104,100...204,114,182
Ensembl chr 1:204,104,101...204,114,268
|
|
G |
Exosc4 |
exosome component 4 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of EXOSC4 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 7:108,047,831...108,050,573
Ensembl chr 7:108,047,831...108,050,573
|
|
G |
Exosc8 |
exosome component 8 |
increases expression |
ISO |
fenpyroximate results in increased expression of EXOSC8 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 2:138,930,405...138,937,009
Ensembl chr 2:138,930,405...138,936,928
|
|
G |
Fam72a |
family with sequence similarity 72, member A |
increases expression |
ISO |
fenpyroximate results in increased expression of FAM72A mRNA |
CTD |
PMID:33512557 |
|
NCBI chr13:42,967,701...42,979,083
Ensembl chr13:42,967,578...42,984,208
|
|
G |
Fbl |
fibrillarin |
increases expression |
ISO |
fenpyroximate results in increased expression of FBL mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:83,469,832...83,478,932
Ensembl chr 1:83,469,832...83,478,932
|
|
G |
Fbxo7 |
F-box protein 7 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of FBXO7 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 7:17,809,224...17,837,549
Ensembl chr 7:17,809,231...17,837,530
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
increases expression |
ISO |
fenpyroximate results in increased expression of FGF2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221
|
|
G |
Fth1 |
ferritin heavy chain 1 |
increases expression |
ISO |
fenpyroximate results in increased expression of FTH1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:206,627,142...206,629,430
Ensembl chr 1:206,627,103...206,725,424
|
|
G |
Ftl1 |
ferritin light chain 1 |
increases expression |
ISO |
fenpyroximate results in increased expression of FTL mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:95,936,387...95,938,234
Ensembl chr 1:95,936,387...95,939,725 Ensembl chr10:95,936,387...95,939,725 Ensembl chr 2:95,936,387...95,939,725
|
|
G |
G6pc1 |
glucose-6-phosphatase catalytic subunit 1 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of G6PC1 mRNA |
CTD |
PMID:32194361 |
|
NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804
|
|
G |
G6pd |
glucose-6-phosphate dehydrogenase |
decreases expression |
ISO |
fenpyroximate results in decreased expression of G6PD mRNA |
CTD |
PMID:33512557 |
|
NCBI chr X:152,201,081...152,220,863
Ensembl chr X:152,201,098...152,220,801
|
|
G |
Gadd45b |
growth arrest and DNA-damage-inducible, beta |
increases expression |
ISO |
fenpyroximate results in increased expression of GADD45B mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 7:8,778,004...8,780,306
Ensembl chr 7:8,778,007...8,780,046
|
|
G |
Gadd45g |
growth arrest and DNA-damage-inducible, gamma |
increases expression |
ISO |
fenpyroximate results in increased expression of GADD45G mRNA |
CTD |
PMID:33512557 |
|
NCBI chr17:13,376,842...13,378,587
Ensembl chr17:13,376,839...13,378,610
|
|
G |
Gap43 |
growth associated protein 43 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of GAP43 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr11:58,376,371...58,470,047
Ensembl chr11:58,376,371...58,470,045
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
increases expression |
ISO |
fenpyroximate results in increased expression of GCLM mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535
|
|
G |
Gdf15 |
growth differentiation factor 15 |
increases expression |
ISO |
fenpyroximate results in increased expression of GDF15 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr16:18,804,457...18,808,043
Ensembl chr16:18,805,239...18,808,055
|
|
G |
Gfus |
GDP-L-fucose synthase |
increases expression |
ISO |
fenpyroximate results in increased expression of GFUS mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 7:107,612,087...107,617,005
Ensembl chr 7:107,612,094...107,616,948
|
|
G |
Gldc |
glycine decarboxylase |
decreases expression |
ISO |
fenpyroximate results in decreased expression of GLDC mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:227,883,249...227,962,119
Ensembl chr 1:227,883,249...227,962,097
|
|
G |
Gli3 |
GLI family zinc finger 3 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of GLI3 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr17:49,438,567...49,709,712
Ensembl chr17:49,438,567...49,709,712
|
|
G |
Glrx |
glutaredoxin |
decreases expression |
ISO |
fenpyroximate results in decreased expression of GLRX mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 2:5,341,873...5,351,686
Ensembl chr 2:5,341,885...5,351,680
|
|
G |
Gnai2 |
G protein subunit alpha i2 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of GNAI2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 8:108,288,401...108,309,009
Ensembl chr 8:108,288,401...108,308,979
|
|
G |
Grb10 |
growth factor receptor bound protein 10 |
increases expression |
ISO |
fenpyroximate results in increased expression of GRB10 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr14:86,495,051...86,602,800
Ensembl chr14:86,495,054...86,602,806
|
|
G |
Grm4 |
glutamate metabotropic receptor 4 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of GRM4 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr20:5,484,172...5,572,821
Ensembl chr20:5,481,124...5,572,821
|
|
G |
Gstm2 |
glutathione S-transferase mu 2 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of GSTM2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 2:195,624,015...195,628,774
Ensembl chr 2:195,544,426...195,628,961
|
|
G |
H1f2 |
H1.2 linker histone, cluster member |
increases expression |
ISO |
fenpyroximate results in increased expression of H1-2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr17:41,391,106...41,392,597
Ensembl chr17:41,388,477...41,392,635
|
|
G |
H2bc3 |
H2B clustered histone 3 |
increases expression |
ISO |
fenpyroximate results in increased expression of H2BC3 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr17:41,380,056...41,380,686
|
|
G |
H2bc9 |
H2B clustered histone 9 |
increases expression |
ISO |
fenpyroximate results in increased expression of H2BC9 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr17:42,470,593...42,478,590
|
|
G |
Hapstr1 |
HUWE1 associated protein modifying stress responses |
increases expression |
ISO |
fenpyroximate results in increased expression of HAPSTR1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr10:6,746,037...6,774,992
Ensembl chr10:6,746,048...6,774,992
|
|
G |
Hcst |
hematopoietic cell signal transducer |
increases expression |
ISO |
fenpyroximate results in increased expression of HCST mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:85,676,976...85,679,083
Ensembl chr 1:85,676,979...85,679,012
|
|
G |
Hdac2 |
histone deacetylase 2 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of HDAC2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr20:40,548,244...40,571,609
Ensembl chr20:40,548,250...40,571,609
|
|
G |
Herpud1 |
homocysteine inducible ER protein with ubiquitin like domain 1 |
increases expression |
ISO |
fenpyroximate results in increased expression of HERPUD1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr19:10,598,411...10,609,002
Ensembl chr19:10,598,417...10,618,424
|
|
G |
Hes1 |
hes family bHLH transcription factor 1 |
increases expression |
ISO |
fenpyroximate results in increased expression of HES1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr11:70,705,763...70,708,176
Ensembl chr11:70,705,764...70,708,192
|
|
G |
Hist1h2af |
histone cluster 1 H2A family member F |
increases expression |
ISO |
fenpyroximate results in increased expression of H2AC8 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr17:41,379,404...41,379,796
Ensembl chr17:41,379,404...41,379,796
|
|
G |
Hist1h2ah |
histone cluster 1 H2A family member H |
increases expression |
ISO |
fenpyroximate results in increased expression of H2AC11 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr17:41,384,521...41,385,018
|
|
G |
Hist1h2al1 |
histone cluster 1 H2A family like 1 |
increases expression |
ISO |
fenpyroximate results in increased expression of H2AC6 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr17:42,707,954...42,708,420
|
|
G |
Hist1h2bd |
histone cluster 1 H2B family member D |
increases expression |
ISO |
fenpyroximate results in increased expression of H2BC5 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr17:42,792,887...42,793,268
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression |
ISO |
fenpyroximate results in increased expression of HMOX1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hnrnpm |
heterogeneous nuclear ribonucleoprotein M |
decreases expression |
ISO |
fenpyroximate results in decreased expression of HNRNPM mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 7:14,438,703...14,476,781
Ensembl chr 7:14,438,688...14,476,762
|
|
G |
Hsp90b1 |
heat shock protein 90 beta family member 1 |
increases expression |
ISO |
fenpyroximate results in increased expression of HSP90B1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 7:21,110,431...21,124,762
Ensembl chr 7:21,110,457...21,124,788
|
|
G |
Hspa1b |
heat shock protein family A (Hsp70) member 1B |
increases expression |
ISO |
fenpyroximate results in increased expression of HSPA1B mRNA |
CTD |
PMID:33512557 |
|
NCBI chr20:3,855,104...3,859,148
Ensembl chr20:3,856,006...3,873,240 Ensembl chr20:3,856,006...3,873,240
|
|
G |
Hspe1 |
heat shock protein family E (Hsp10) member 1 |
increases expression |
ISO |
fenpyroximate results in increased expression of HSPE1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 9:56,589,912...56,593,000
Ensembl chr 9:56,589,789...56,593,089
|
|
G |
Htatsf1 |
HIV-1 Tat specific factor 1 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of HTATSF1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr X:134,935,426...134,949,607
Ensembl chr X:134,935,426...134,949,607
|
|
G |
Id1 |
inhibitor of DNA binding 1 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of ID1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 3:141,210,666...141,212,420
Ensembl chr 3:141,211,267...141,212,419
|
|
G |
Id2 |
inhibitor of DNA binding 2 |
increases expression |
ISO |
fenpyroximate results in increased expression of ID2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 6:41,740,556...41,742,393
Ensembl chr 6:41,728,946...41,744,400
|
|
G |
Ifrd1 |
interferon-related developmental regulator 1 |
increases expression |
ISO |
fenpyroximate results in increased expression of IFRD1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 6:57,269,395...57,317,833
Ensembl chr 6:57,269,384...57,288,990
|
|
G |
Igf1r |
insulin-like growth factor 1 receptor |
decreases expression |
ISO |
fenpyroximate results in decreased expression of IGF1R mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:121,549,831...121,838,548
Ensembl chr 1:121,550,743...121,831,777
|
|
G |
Igfbp2 |
insulin-like growth factor binding protein 2 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of IGFBP2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 9:74,415,574...74,442,945
Ensembl chr 9:74,415,546...74,442,937
|
|
G |
Ina |
internexin neuronal intermediate filament protein, alpha |
decreases expression |
ISO |
fenpyroximate results in decreased expression of INA mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:245,896,775...245,908,330
Ensembl chr 1:245,896,775...245,908,330
|
|
G |
Ipo5 |
importin 5 |
increases expression |
ISO |
fenpyroximate results in increased expression of IPO5 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr15:97,990,755...98,041,074
Ensembl chr15:98,005,299...98,041,126
|
|
G |
Itpr2 |
inositol 1,4,5-trisphosphate receptor, type 2 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of ITPR2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 4:179,028,594...179,434,657
Ensembl chr 4:179,027,281...179,404,164
|
|
G |
Jmjd6 |
jumonji domain containing 6, arginine demethylase and lysine hydroxylase |
increases expression |
ISO |
fenpyroximate results in increased expression of JMJD6 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr10:102,041,131...102,047,182
Ensembl chr10:102,041,120...102,047,182
|
|
G |
Kdm3a |
lysine demethylase 3A |
decreases expression |
ISO |
fenpyroximate results in decreased expression of KDM3A mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 4:103,630,907...103,675,073
Ensembl chr 4:103,630,908...103,675,073
|
|
G |
Kdm5b |
lysine demethylase 5B |
decreases expression |
ISO |
fenpyroximate results in decreased expression of KDM5B mRNA |
CTD |
PMID:33512557 |
|
NCBI chr13:46,001,589...46,073,868
Ensembl chr13:46,002,542...46,073,872
|
|
G |
Kif15 |
kinesin family member 15 |
increases expression |
ISO |
fenpyroximate results in increased expression of KIF15 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 8:122,601,888...122,672,750
Ensembl chr 8:122,601,897...122,672,750
|
|
G |
Kif20a |
kinesin family member 20A |
increases expression |
ISO |
fenpyroximate results in increased expression of KIF20A mRNA |
CTD |
PMID:33512557 |
|
NCBI chr18:26,230,294...26,238,780
Ensembl chr18:26,230,230...26,238,780
|
|
G |
Kif5c |
kinesin family member 5C |
decreases expression |
ISO |
fenpyroximate results in decreased expression of KIF5C mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 3:34,032,082...34,185,597
Ensembl chr 3:34,032,105...34,182,413
|
|
G |
Klhl24 |
kelch-like family member 24 |
increases expression |
ISO |
fenpyroximate results in increased expression of KLHL24 mRNA |
CTD |
PMID:34642769 |
|
NCBI chr11:80,843,621...80,877,649
Ensembl chr11:80,846,755...80,877,636
|
|
G |
Knl1 |
kinetochore scaffold 1 |
increases expression |
ISO |
fenpyroximate results in increased expression of KNL1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 3:106,029,627...106,091,915
Ensembl chr 3:106,029,661...106,091,915
|
|
G |
Kyat3 |
kynurenine aminotransferase 3 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of KYAT3 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 2:231,701,881...231,747,462
Ensembl chr 2:231,701,963...231,747,227
|
|
G |
Loxl1 |
lysyl oxidase-like 1 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of LOXL1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 8:58,691,763...58,716,365
Ensembl chr 8:58,692,593...58,716,356
|
|
G |
Lrrc41 |
leucine rich repeat containing 41 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of LRRC41 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 5:129,554,547...129,575,450
Ensembl chr 5:129,554,547...129,575,449
|
|
G |
Manf |
mesencephalic astrocyte-derived neurotrophic factor |
increases expression |
ISO |
fenpyroximate results in increased expression of MANF mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 8:107,500,856...107,551,595
Ensembl chr 8:107,548,352...107,551,438
|
|
G |
Map1b |
microtubule-associated protein 1B |
decreases expression |
ISO |
fenpyroximate results in decreased expression of MAP1B mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 2:30,817,261...30,910,458
Ensembl chr 2:30,817,261...30,910,317
|
|
G |
Map6 |
microtubule-associated protein 6 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of MAP6 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:153,568,020...153,634,415
Ensembl chr 1:153,568,368...153,634,414
|
|
G |
Mcm7 |
minichromosome maintenance complex component 7 |
increases expression |
ISO |
fenpyroximate results in increased expression of MCM7 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr12:17,042,207...17,049,470
Ensembl chr12:17,042,212...17,050,063
|
|
G |
Mdk |
midkine |
increases expression |
ISO |
fenpyroximate results in increased expression of MDK mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 3:77,901,134...77,903,997
Ensembl chr 3:77,901,158...77,903,130
|
|
G |
Me1 |
malic enzyme 1 |
increases expression |
ISO |
fenpyroximate results in increased expression of ME1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 8:87,549,043...87,660,251
Ensembl chr 8:87,549,043...87,660,304
|
|
G |
Mki67 |
marker of proliferation Ki-67 |
increases expression |
ISO |
fenpyroximate results in increased expression of MKI67 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762
|
|
G |
Mllt11 |
MLLT11, transcription factor 7 cofactor |
decreases expression |
ISO |
fenpyroximate results in decreased expression of MLLT11 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 2:182,795,790...182,804,960
Ensembl chr 2:182,795,790...182,797,199
|
|
G |
Mnat1 |
MNAT1 component of CDK activating kinase |
decreases expression |
ISO |
fenpyroximate results in decreased expression of MNAT1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 6:91,814,703...91,971,945
Ensembl chr 6:91,814,749...91,970,744
|
|
G |
Morn2 |
MORN repeat containing 2 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of MORN2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 6:14,718,799...14,725,281
|
|
G |
Msi2 |
musashi RNA-binding protein 2 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of MSI2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr10:73,143,760...73,510,566
Ensembl chr10:73,147,380...73,510,157
|
|
G |
Mta1 |
metastasis associated 1 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of MTA1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 6:132,178,608...132,217,641
Ensembl chr 6:132,178,853...132,217,641
|
|
G |
Mthfd2 |
methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase |
increases expression |
ISO |
fenpyroximate results in increased expression of MTHFD2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 4:115,811,135...115,822,663
Ensembl chr 4:115,811,139...115,822,608
|
|
G |
Nav1 |
neuron navigator 1 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of NAV1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr13:46,866,972...47,119,368
Ensembl chr13:46,873,689...47,126,449
|
|
G |
Ncan |
neurocan |
decreases expression |
ISO |
fenpyroximate results in decreased expression of NCAN mRNA |
CTD |
PMID:33512557 |
|
NCBI chr16:19,301,969...19,328,436
Ensembl chr16:19,301,969...19,328,436
|
|
G |
Ndufa1 |
NADH:ubiquinone oxidoreductase subunit A1 |
increases expression |
ISO |
fenpyroximate results in increased expression of NDUFA1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr X:116,424,223...116,427,875
Ensembl chr X:116,424,223...116,428,633
|
|
G |
Nek2 |
NIMA-related kinase 2 |
increases expression |
ISO |
fenpyroximate results in increased expression of NEK2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr13:103,405,818...103,419,063
Ensembl chr13:103,405,819...103,419,051
|
|
G |
Nfatc3 |
nuclear factor of activated T-cells 3 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of NFATC3 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr19:33,960,643...34,035,150
Ensembl chr19:33,960,852...34,035,150
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
increases activity |
ISO |
fenpyroximate results in increased activity of NFE2L2 protein |
CTD |
PMID:30818834 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfil3 |
nuclear factor, interleukin 3 regulated |
decreases expression |
ISO |
fenpyroximate results in decreased expression of NFIL3 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr17:12,280,499...12,295,728
Ensembl chr17:12,280,484...12,295,858
|
|
G |
Nfkbib |
NFKB inhibitor beta |
decreases expression |
ISO |
fenpyroximate results in decreased expression of NFKBIB mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:84,046,292...84,053,862
Ensembl chr 1:84,046,295...84,053,862
|
|
G |
Nit1 |
nitrilase 1 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of NIT1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr13:83,769,888...83,773,324
Ensembl chr13:83,765,941...83,773,332
|
|
G |
Nmnat3 |
nicotinamide nucleotide adenylyltransferase 3 |
decreases response to substance |
ISO |
NMNAT3 protein results in decreased susceptibility to fenpyroximate |
CTD |
PMID:18463239 |
|
NCBI chr 8:98,892,168...99,003,912
Ensembl chr 8:98,873,398...99,020,645
|
|
G |
Nos3 |
nitric oxide synthase 3 |
increases expression |
ISO |
fenpyroximate results in increased expression of NOS3 mRNA |
CTD |
PMID:34642769 |
|
NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
|
|
G |
Notch3 |
notch receptor 3 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of NOTCH3 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 7:11,132,984...11,184,025
Ensembl chr 7:11,133,706...11,184,025
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
increases expression |
ISO |
fenpyroximate results in increased expression of NQO1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nr2f1 |
nuclear receptor subfamily 2, group F, member 1 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of NR2F1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 2:8,040,375...8,050,123
Ensembl chr 2:8,040,377...8,050,123
|
|
G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
increases expression |
ISO |
fenpyroximate results in increased expression of NR3C1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr18:31,271,681...31,393,320
Ensembl chr18:31,271,681...31,393,375
|
|
G |
Nr5a1 |
nuclear receptor subfamily 5, group A, member 1 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of NR5A1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 3:22,464,786...22,486,328
Ensembl chr 3:22,465,502...22,486,328
|
|
G |
Nrcam |
neuronal cell adhesion molecule |
decreases expression |
ISO |
fenpyroximate results in decreased expression of NRCAM mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 6:61,402,813...61,698,536
Ensembl chr 6:61,329,863...61,702,992
|
|
G |
Nrxn1 |
neurexin 1 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of NRXN1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 6:3,177,788...4,323,848
Ensembl chr 6:3,177,897...4,322,710
|
|
G |
Ntrk1 |
neurotrophic receptor tyrosine kinase 1 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of NTRK1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 2:173,236,961...173,253,806
Ensembl chr 2:173,236,963...173,253,770
|
|
G |
Oaz1 |
ornithine decarboxylase antizyme 1 |
increases expression |
ISO |
fenpyroximate results in increased expression of OAZ1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 7:8,883,855...8,886,315
Ensembl chr 7:8,883,851...8,886,310
|
|
G |
Olfml2b |
olfactomedin-like 2B |
decreases expression |
ISO |
fenpyroximate results in decreased expression of OLFML2B mRNA |
CTD |
PMID:33512557 |
|
NCBI chr13:82,869,414...82,906,607
Ensembl chr13:82,869,433...82,906,607
|
|
G |
Ostc |
oligosaccharyltransferase complex non-catalytic subunit |
increases expression |
ISO |
fenpyroximate results in increased expression of OSTC mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 2:219,250,549...219,266,076
Ensembl chr 2:219,236,952...219,266,107
|
|
G |
Pafah1b3 |
platelet-activating factor acetylhydrolase 1b, catalytic subunit 3 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of PAFAH1B3 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:80,881,263...80,883,789
Ensembl chr 1:80,881,309...80,883,893
|
|
G |
Park7 |
Parkinsonism associated deglycase |
decreases response to substance |
ISO |
PARK7 protein results in decreased susceptibility to fenpyroximate |
CTD |
PMID:21219333 |
|
NCBI chr 5:161,353,718...161,376,993
Ensembl chr 5:161,353,719...161,376,970
|
|
G |
Parp2 |
poly (ADP-ribose) polymerase 2 |
increases expression |
ISO |
fenpyroximate results in increased expression of PARP2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr15:24,034,069...24,044,340
Ensembl chr15:24,034,106...24,044,338
|
|
G |
Pdia6 |
protein disulfide isomerase family A, member 6 |
increases expression |
ISO |
fenpyroximate results in increased expression of PDIA6 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 6:40,062,980...40,080,223
Ensembl chr 6:40,062,926...40,080,613
|
|
G |
Pebp1 |
phosphatidylethanolamine binding protein 1 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of PEBP1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr12:39,302,864...39,307,064
Ensembl chr12:39,302,840...39,307,862
|
|
G |
Peg10 |
paternally expressed 10 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of PEG10 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 4:32,842,441...32,855,639
Ensembl chr 4:32,848,493...32,852,621
|
|
G |
Pfkp |
phosphofructokinase, platelet |
increases expression |
ISO |
fenpyroximate results in increased expression of PFKP mRNA |
CTD |
PMID:34642769 |
|
NCBI chr17:63,729,743...63,794,026
Ensembl chr17:63,729,780...63,794,018
|
|
G |
Pgm3 |
phosphoglucomutase 3 |
increases expression |
ISO |
fenpyroximate results in increased expression of PGM3 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 8:87,518,317...87,536,021
Ensembl chr 8:87,517,701...87,536,022
|
|
G |
Pgr |
progesterone receptor |
multiple interactions |
ISO |
fenpyroximate inhibits the reaction [Promegestone results in increased activity of PGR protein] |
CTD |
PMID:30818834 |
|
NCBI chr 8:6,072,673...6,131,552
Ensembl chr 8:6,072,673...6,131,344
|
|
G |
Phgdh |
phosphoglycerate dehydrogenase |
increases expression |
ISO |
fenpyroximate results in increased expression of PHGDH mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 2:185,906,962...185,936,054
Ensembl chr 2:185,906,966...185,935,944
|
|
G |
Phlda1 |
pleckstrin homology-like domain, family A, member 1 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of PHLDA1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 7:46,967,433...46,969,637
Ensembl chr 7:46,967,409...46,969,861
|
|
G |
Pik3c2b |
phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 beta |
decreases expression |
ISO |
fenpyroximate results in decreased expression of PIK3C2B mRNA |
CTD |
PMID:33512557 |
|
NCBI chr13:44,494,673...44,555,663
Ensembl chr13:44,495,050...44,555,612
|
|
G |
Pink1 |
PTEN induced kinase 1 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of PINK1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 5:150,530,523...150,542,635
Ensembl chr 5:150,530,523...150,542,635
|
|
G |
Pip4k2b |
phosphatidylinositol-5-phosphate 4-kinase type 2 beta |
decreases expression |
ISO |
fenpyroximate results in decreased expression of PIP4K2B mRNA |
CTD |
PMID:33512557 |
|
NCBI chr10:82,706,016...82,734,938
Ensembl chr10:82,701,098...82,734,938
|
|
G |
Pitpna |
phosphatidylinositol transfer protein, alpha |
decreases expression |
ISO |
fenpyroximate results in decreased expression of PITPNA mRNA |
CTD |
PMID:33512557 |
|
NCBI chr10:60,430,712...60,473,564
Ensembl chr10:60,430,748...60,471,342
|
|
G |
Plin2 |
perilipin 2 |
increases expression |
ISO |
fenpyroximate results in increased expression of PLIN2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 5:101,156,648...101,211,738
Ensembl chr 5:101,154,411...101,242,319
|
|
G |
Pole3 |
DNA polymerase epsilon 3, accessory subunit |
increases expression |
ISO |
fenpyroximate results in increased expression of POLE3 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 5:75,973,941...75,977,175
Ensembl chr 5:75,974,717...75,977,231 Ensembl chr 7:75,974,717...75,977,231
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
multiple interactions |
ISO |
fenpyroximate inhibits the reaction [PPARGC1A protein results in increased activity of ESRRA protein] |
CTD |
PMID:30818834 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Ppp2r1a |
protein phosphatase 2 scaffold subunit A alpha |
decreases expression |
ISO |
fenpyroximate results in decreased expression of PPP2R1A mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:60,540,223...60,559,467
Ensembl chr 1:60,540,194...60,560,129
|
|
G |
Prkag1 |
protein kinase AMP-activated non-catalytic subunit gamma 1 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of PRKAG1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 7:129,963,105...129,980,532
Ensembl chr 7:129,963,105...129,980,561
|
|
G |
Prkar1a |
protein kinase cAMP-dependent type I regulatory subunit alpha |
decreases expression |
ISO |
fenpyroximate results in decreased expression of PRKAR1A mRNA |
CTD |
PMID:33512557 |
|
NCBI chr10:94,621,042...94,639,534
Ensembl chr10:94,620,039...94,639,041
|
|
G |
Prkn |
parkin RBR E3 ubiquitin protein ligase |
decreases expression |
ISO |
fenpyroximate results in decreased expression of PRKN mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:48,688,651...49,882,520
Ensembl chr 1:48,690,556...49,882,555
|
|
G |
Prr11 |
proline rich 11 |
increases expression |
ISO |
fenpyroximate results in increased expression of PRR11 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr10:71,898,858...71,943,325
Ensembl chr10:71,901,202...71,921,012
|
|
G |
Psat1 |
phosphoserine aminotransferase 1 |
increases expression |
ISO |
fenpyroximate results in increased expression of PSAT1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:213,196,709...213,218,564
Ensembl chr 1:213,196,709...213,218,682
|
|
G |
Psma1 |
proteasome 20S subunit alpha 1 |
increases expression |
ISO |
fenpyroximate results in increased expression of PSMA1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:168,442,421...168,453,440
Ensembl chr 1:168,440,936...168,453,472
|
|
G |
Ptk2b |
protein tyrosine kinase 2 beta |
decreases expression |
ISO |
fenpyroximate results in decreased expression of PTK2B mRNA |
CTD |
PMID:33512557 |
|
NCBI chr15:40,360,722...40,481,235
Ensembl chr15:40,360,723...40,481,282
|
|
G |
Ripk1 |
receptor interacting serine/threonine kinase 1 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of RIPK1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr17:30,839,639...30,871,824
Ensembl chr17:30,839,650...30,871,824
|
|
G |
Rnf4 |
ring finger protein 4 |
increases expression |
ISO |
fenpyroximate results in increased expression of RNF4 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr14:76,401,292...76,423,270
Ensembl chr14:76,401,299...76,422,566
|
|
G |
Rnps1 |
RNA binding protein with serine rich domain 1 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of RNPS1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr10:13,445,516...13,455,858
Ensembl chr10:13,445,653...13,455,858
|
|
G |
Rpa3 |
replication protein A3 |
increases expression |
ISO |
fenpyroximate results in increased expression of RPA3 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 4:36,304,649...36,307,755
Ensembl chr 4:36,304,651...36,307,709
|
|
G |
Rpl11 |
ribosomal protein L11 |
increases expression |
ISO |
fenpyroximate results in increased expression of RPL11 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 5:148,274,060...148,277,708
Ensembl chr 5:148,274,069...148,277,599
|
|
G |
Rpl17 |
ribosomal protein L17 |
increases expression |
ISO |
fenpyroximate results in increased expression of RPL17 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr18:68,581,141...68,584,253
Ensembl chr18:68,581,098...68,584,253 Ensembl chr 3:68,581,098...68,584,253
|
|
G |
Rpl27 |
ribosomal protein L27 |
increases expression |
ISO |
fenpyroximate results in increased expression of RPL27 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr10:86,375,511...86,379,210
Ensembl chr10:86,375,454...86,379,193
|
|
G |
Rpl28 |
ribosomal protein L28 |
increases expression |
ISO |
fenpyroximate results in increased expression of RPL28 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:69,052,148...69,054,735
Ensembl chr 1:69,053,203...69,055,032
|
|
G |
Rpl32 |
ribosomal protein L32 |
increases expression |
ISO |
fenpyroximate results in increased expression of RPL32 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 4:148,864,048...148,867,612
Ensembl chr 4:148,864,044...148,867,612 Ensembl chr 3:148,864,044...148,867,612
|
|
G |
Rpl36 |
ribosomal protein L36 |
increases expression |
ISO |
fenpyroximate results in increased expression of RPL36 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 9:1,441,986...1,447,397
Ensembl chr 6:98,809,534...98,809,897 Ensembl chr 5:98,809,534...98,809,897
|
|
G |
Rpl36al1 |
ribosomal protein L36A like 1 |
increases expression |
ISO |
fenpyroximate results in increased expression of RPL36AL mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 6:87,654,808...87,656,202
Ensembl chr X:97,766,179...97,768,892 Ensembl chr10:97,766,179...97,768,892 Ensembl chr20:97,766,179...97,768,892
|
|
G |
Rpl9 |
ribosomal protein L9 |
increases expression |
ISO |
fenpyroximate results in increased expression of RPL9 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr14:42,893,945...42,897,140
Ensembl chr14:42,893,942...42,897,136 Ensembl chr 3:42,893,942...42,897,136 Ensembl chr 1:42,893,942...42,897,136
|
|
G |
Rps13 |
ribosomal protein S13 |
increases expression |
ISO |
fenpyroximate results in increased expression of RPS13 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:170,572,925...170,575,355
Ensembl chr 1:170,572,921...170,575,355 Ensembl chr 3:170,572,921...170,575,355
|
|
G |
Rps18 |
ribosomal protein S18 |
increases expression |
ISO |
fenpyroximate results in increased expression of RPS18 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr20:4,931,427...4,935,538
Ensembl chr20:4,931,768...4,938,315
|
|
G |
Rps2 |
ribosomal protein S2 |
increases expression |
ISO |
fenpyroximate results in increased expression of RPS2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr10:13,747,316...13,749,165
Ensembl chr10:13,747,301...13,749,163
|
|
G |
Rps25 |
ribosomal protein s25 |
increases expression |
ISO |
fenpyroximate results in increased expression of RPS25 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 8:44,733,623...44,735,999
Ensembl chr 8:44,733,029...44,737,271 Ensembl chr 8:44,733,029...44,737,271
|
|
G |
Rps27a |
ribosomal protein S27a |
increases expression |
ISO |
fenpyroximate results in increased expression of RPS27A mRNA |
CTD |
PMID:33512557 |
|
NCBI chr14:103,285,734...103,288,011
Ensembl chr14:103,285,734...103,288,011 Ensembl chr 5:103,285,734...103,288,011 Ensembl chr 5:103,285,734...103,288,011
|
|
G |
Rps3 |
ribosomal protein S3 |
increases expression |
ISO |
fenpyroximate results in increased expression of RPS3 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:153,778,363...153,783,663
Ensembl chr 1:153,777,472...153,783,680
|
|
G |
Rps5 |
ribosomal protein S5 |
increases expression |
ISO |
fenpyroximate results in increased expression of RPS5 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:73,538,776...73,543,073
Ensembl chr 1:73,538,776...73,543,073
|
|
G |
Rps7 |
ribosomal protein S7 |
increases expression |
ISO |
fenpyroximate results in increased expression of RPS7 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 6:45,266,200...45,271,064
Ensembl chr 6:45,223,980...45,271,145 Ensembl chr 5:45,223,980...45,271,145
|
|
G |
Rsl24d1 |
ribosomal L24 domain containing 1 |
increases expression |
ISO |
fenpyroximate results in increased expression of RSL24D1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 8:73,852,991...73,861,996
Ensembl chr 8:73,852,996...73,862,001
|
|
G |
S100a13 |
S100 calcium binding protein A13 |
increases expression |
ISO |
fenpyroximate results in increased expression of S100A13 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 2:175,999,439...176,005,933
|
|
G |
S100a4 |
S100 calcium-binding protein A4 |
increases expression |
ISO |
fenpyroximate results in increased expression of S100A4 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 2:176,090,951...176,093,258
Ensembl chr 2:176,091,804...176,093,254
|
|
G |
Satb1 |
SATB homeobox 1 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of SATB1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 9:4,677,817...4,773,061
Ensembl chr 9:4,680,920...4,753,251
|
|
G |
Selenos |
selenoprotein S |
increases expression |
ISO |
fenpyroximate results in increased expression of SELENOS mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:119,659,779...119,669,546
Ensembl chr 1:119,659,751...119,669,833
|
|
G |
Sema4b |
semaphorin 4B |
decreases expression |
ISO |
fenpyroximate results in decreased expression of SEMA4B mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:134,136,646...134,177,777
Ensembl chr 1:134,149,536...134,177,775
|
|
G |
Sema6d |
semaphorin 6D |
decreases expression |
ISO |
fenpyroximate results in decreased expression of SEMA6D mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 3:111,883,415...111,941,100
Ensembl chr 3:111,883,872...111,941,094
|
|
G |
Septin10 |
septin 10 |
increases expression |
ISO |
fenpyroximate results in increased expression of SEPTIN10 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr20:27,101,764...27,194,997
Ensembl chr20:27,101,752...27,194,780
|
|
G |
Sertad1 |
SERTA domain containing 1 |
increases expression |
ISO |
fenpyroximate results in increased expression of SERTAD1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:82,775,692...82,778,961
Ensembl chr 1:82,775,252...82,779,091
|
|
G |
Sesn2 |
sestrin 2 |
increases expression |
ISO |
fenpyroximate results in increased expression of SESN2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 5:144,702,287...144,721,241
Ensembl chr 5:144,701,530...144,721,260
|
|
G |
Shcbp1 |
SHC binding and spindle associated 1 |
increases expression |
ISO |
fenpyroximate results in increased expression of SHCBP1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr16:84,672,277...84,703,843
Ensembl chr16:84,672,321...84,703,844
|
|
G |
Slc17a6 |
solute carrier family 17 member 6 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of SLC17A6 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:101,212,489...101,252,543
Ensembl chr 1:101,212,489...101,252,542
|
|
G |
Slc35a5 |
solute carrier family 35, member A5 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of SLC35A5 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr11:55,653,376...55,674,476
Ensembl chr11:55,653,394...55,674,473
|
|
G |
Slc38a1 |
solute carrier family 38, member 1 |
increases expression |
ISO |
fenpyroximate results in increased expression of SLC38A1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 7:127,733,230...127,802,541
Ensembl chr 7:127,738,226...127,802,218
|
|
G |
Slc3a2 |
solute carrier family 3 member 2 |
increases expression |
ISO |
fenpyroximate results in increased expression of SLC3A2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:205,604,468...205,618,931
Ensembl chr 1:205,604,468...205,618,931
|
|
G |
Slc7a5 |
solute carrier family 7 member 5 |
increases expression |
ISO |
fenpyroximate results in increased expression of SLC7A5 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr19:49,935,220...49,963,823
Ensembl chr19:49,935,220...49,963,823
|
|
G |
Smc3 |
structural maintenance of chromosomes 3 |
increases expression |
ISO |
fenpyroximate results in increased expression of SMC3 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:252,601,422...252,644,522
Ensembl chr 1:252,601,753...252,644,522
|
|
G |
Smndc1 |
survival motor neuron domain containing 1 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of SMNDC1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:252,389,675...252,400,749
Ensembl chr 1:252,389,673...252,401,616
|
|
G |
Snai2 |
snail family transcriptional repressor 2 |
increases expression |
ISO |
fenpyroximate results in increased expression of SNAI2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr11:86,182,788...86,186,203
Ensembl chr11:86,181,909...86,186,200
|
|
G |
Snca |
synuclein alpha |
increases response to substance |
ISO |
SNCA protein results in increased susceptibility to fenpyroximate |
CTD |
PMID:16239214 |
|
NCBI chr 4:89,696,420...89,797,240
Ensembl chr 4:89,696,420...89,796,262
|
|
G |
Snrpd3 |
small nuclear ribonucleoprotein D3 polypeptide |
increases expression |
ISO |
fenpyroximate results in increased expression of SNRPD3 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr20:13,130,112...13,145,947
Ensembl chr20:13,130,119...13,145,978
|
|
G |
Socs2 |
suppressor of cytokine signaling 2 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of SOCS2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 7:30,006,360...30,045,161
Ensembl chr 7:30,008,578...30,043,548
|
|
G |
Spag5 |
sperm associated antigen 5 |
increases expression |
ISO |
fenpyroximate results in increased expression of SPAG5 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr10:63,198,717...63,216,746
Ensembl chr10:63,198,768...63,216,745
|
|
G |
Spc25 |
SPC25 component of NDC80 kinetochore complex |
increases expression |
ISO |
fenpyroximate results in increased expression of SPC25 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 3:53,930,013...53,988,940
Ensembl chr 3:53,975,704...53,988,959
|
|
G |
Spdef |
SAM pointed domain containing ets transcription factor |
decreases expression |
ISO |
fenpyroximate results in decreased expression of SPDEF mRNA |
CTD |
PMID:33512557 |
|
NCBI chr20:5,771,440...5,785,893
Ensembl chr20:5,771,441...5,785,893
|
|
G |
Srsf10 |
serine and arginine rich splicing factor 10 |
increases expression |
ISO |
fenpyroximate results in increased expression of SRSF10 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 5:148,088,759...148,102,964
Ensembl chr 5:148,088,823...148,101,768
|
|
G |
Stk25 |
serine/threonine kinase 25 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of STK25 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 9:94,161,834...94,174,095
Ensembl chr 9:94,161,836...94,174,244
|
|
G |
Sytl1 |
synaptotagmin-like 1 |
increases expression |
ISO |
fenpyroximate results in increased expression of SYTL1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 5:145,452,524...145,462,940
Ensembl chr 5:145,422,669...145,462,940
|
|
G |
Tacc3 |
transforming, acidic coiled-coil containing protein 3 |
increases expression |
ISO |
fenpyroximate results in increased expression of TACC3 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr14:77,051,209...77,065,343
Ensembl chr14:77,051,215...77,065,219
|
|
G |
Tcf4 |
transcription factor 4 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of TCF4 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr18:62,941,739...63,288,126
Ensembl chr18:62,943,782...63,284,425
|
|
G |
Tfdp1 |
transcription factor Dp-1 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of TFDP1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr16:76,162,040...76,200,871
Ensembl chr16:76,162,043...76,200,817
|
|
G |
Tgfb3 |
transforming growth factor, beta 3 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of TGFB3 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 6:105,704,058...105,726,661
Ensembl chr 6:105,704,236...105,726,564
|
|
G |
Thra |
thyroid hormone receptor alpha |
increases activity |
ISO |
fenpyroximate results in increased activity of THRA protein |
CTD |
PMID:20143881 |
|
NCBI chr10:83,701,885...83,729,408
Ensembl chr10:83,700,755...83,729,936
|
|
G |
Tlk2 |
tousled-like kinase 2 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of TLK2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr10:90,154,449...90,248,562
Ensembl chr10:90,156,813...90,248,561
|
|
G |
Tm9sf3 |
transmembrane 9 superfamily member 3 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of TM9SF3 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:240,032,060...240,085,125
Ensembl chr 1:240,035,003...240,084,776
|
|
G |
Tmem185a |
transmembrane protein 185A |
decreases expression |
ISO |
fenpyroximate results in decreased expression of TMEM185A mRNA |
CTD |
PMID:33512557 |
|
NCBI chr X:149,143,026...149,167,757
Ensembl chr X:149,143,031...149,167,757
|
|
G |
Tnc |
tenascin C |
decreases expression |
ISO |
fenpyroximate results in decreased expression of TNC mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 5:77,375,851...77,460,712
Ensembl chr 5:77,375,851...77,460,624
|
|
G |
Top2a |
DNA topoisomerase II alpha |
increases expression |
ISO |
fenpyroximate results in increased expression of TOP2A mRNA |
CTD |
PMID:33512557 |
|
NCBI chr10:83,945,731...83,976,874
Ensembl chr10:83,945,735...83,976,874
|
|
G |
Tp53 |
tumor protein p53 |
increases expression |
ISO |
fenpyroximate results in increased expression of TP53 mRNA |
CTD |
PMID:36933581 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Tpx2 |
TPX2, microtubule nucleation factor |
increases expression |
ISO |
fenpyroximate results in increased expression of TPX2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 3:141,318,428...141,360,684
Ensembl chr 3:141,318,455...141,360,468
|
|
G |
Trib3 |
tribbles pseudokinase 3 |
increases expression |
ISO |
fenpyroximate results in increased expression of TRIB3 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 3:140,809,634...140,815,230
Ensembl chr 3:140,809,043...140,814,497
|
|
G |
Trim13 |
tripartite motif-containing 13 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of TRIM13 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr15:35,733,548...35,772,676
Ensembl chr15:35,734,107...35,772,677
|
|
G |
Trpv1 |
transient receptor potential cation channel, subfamily V, member 1 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of TRPV1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr10:57,851,428...57,876,513
Ensembl chr10:57,851,428...57,876,513
|
|
G |
Tsc22d3 |
TSC22 domain family, member 3 |
increases expression |
ISO |
fenpyroximate results in increased expression of TSC22D3 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr X:104,217,898...104,277,886
Ensembl chr X:104,217,925...104,276,861
|
|
G |
Tsg101 |
tumor susceptibility 101 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of TSG101 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 1:97,412,689...97,442,589
Ensembl chr 1:97,410,848...97,442,554
|
|
G |
Tspan3 |
tetraspanin 3 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of TSPAN3 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 8:56,546,067...56,569,815
Ensembl chr 8:56,546,069...56,569,880
|
|
G |
Tst |
thiosulfate sulfurtransferase |
decreases expression |
ISO |
fenpyroximate results in decreased expression of TST mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 7:109,948,061...109,955,378
Ensembl chr 7:109,948,062...109,957,216
|
|
G |
Tubb2b |
tubulin, beta 2B class IIb |
decreases expression |
ISO |
fenpyroximate results in decreased expression of TUBB2B mRNA |
CTD |
PMID:33512557 |
|
NCBI chr17:30,747,734...30,750,781
Ensembl chr17:30,747,734...30,750,638
|
|
G |
Txndc5 |
thioredoxin domain containing 5 |
increases expression |
ISO |
fenpyroximate results in increased expression of TXNDC5 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr17:26,289,880...26,318,025
Ensembl chr17:26,289,880...26,318,025
|
|
G |
Txnip |
thioredoxin interacting protein |
decreases expression |
ISO |
fenpyroximate results in decreased expression of TXNIP mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 2:184,093,079...184,096,882
Ensembl chr 2:184,092,991...184,096,886
|
|
G |
Txnrd1 |
thioredoxin reductase 1 |
increases expression |
ISO |
fenpyroximate results in increased expression of TXNRD1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 7:20,830,042...20,914,990
Ensembl chr 7:20,830,045...20,907,863
|
|
G |
Uba52 |
ubiquitin A-52 residue ribosomal protein fusion product 1 |
increases expression |
ISO |
fenpyroximate results in increased expression of UBA52 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr16:18,918,614...18,920,807
Ensembl chr16:18,900,616...18,920,807
|
|
G |
Ube2c |
ubiquitin-conjugating enzyme E2C |
increases expression |
ISO |
fenpyroximate results in increased expression of UBE2C mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 3:153,506,636...153,509,036
Ensembl chr 3:153,506,636...153,513,339
|
|
G |
Ube2q2 |
ubiquitin conjugating enzyme E2 Q2 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of UBE2Q2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 8:55,518,402...55,578,342
Ensembl chr 8:55,519,147...55,577,212
|
|
G |
Uqcrq |
ubiquinol-cytochrome c reductase, complex III subunit VII |
increases expression |
ISO |
fenpyroximate results in increased expression of UQCRQ mRNA |
CTD |
PMID:33512557 |
|
NCBI chr10:37,585,864...37,589,328
Ensembl chr10:37,586,888...37,589,169
|
|
G |
Vapb |
VAMP associated protein B and C |
decreases expression |
ISO |
fenpyroximate results in decreased expression of VAPB mRNA |
CTD |
PMID:34642769 |
|
NCBI chr 3:162,535,974...162,578,747
Ensembl chr 3:162,535,905...162,573,763
|
|
G |
Vegfa |
vascular endothelial growth factor A |
increases expression |
ISO |
fenpyroximate results in increased expression of VEGFA mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Vgll4 |
vestigial-like family member 4 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of VGLL4 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 4:147,925,630...148,038,519
Ensembl chr 4:147,927,034...148,038,471
|
|
G |
Vps72 |
vacuolar protein sorting 72 homolog |
decreases expression |
ISO |
fenpyroximate results in decreased expression of VPS72 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 2:182,678,594...182,690,185
Ensembl chr 2:182,678,609...182,690,182
|
|
G |
Wars1 |
tryptophanyl-tRNA synthetase 1 |
increases expression |
ISO |
fenpyroximate results in increased expression of WARS1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 6:127,776,088...127,807,273
Ensembl chr 6:127,776,090...127,807,269
|
|
G |
Xbp1 |
X-box binding protein 1 |
increases expression |
ISO |
fenpyroximate results in increased expression of XBP1 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr14:80,390,629...80,395,713
Ensembl chr14:80,390,643...80,395,693
|
|
G |
Ywhab |
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, beta |
decreases expression |
ISO |
fenpyroximate results in decreased expression of YWHAB mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 3:152,659,663...152,682,105
Ensembl chr 3:152,659,651...152,682,105
|
|
G |
Zbtb41 |
zinc finger and BTB domain containing 41 |
decreases expression |
ISO |
fenpyroximate results in decreased expression of ZBTB41 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr13:51,042,948...51,065,768
Ensembl chr13:51,042,948...51,065,768
|
|
G |
Zfand2a |
zinc finger AN1-type containing 2A |
increases expression |
ISO |
fenpyroximate results in increased expression of ZFAND2A mRNA |
CTD |
PMID:33512557 |
|
NCBI chr12:15,161,601...15,172,679
Ensembl chr12:15,161,639...15,172,677
|
|
G |
Zranb2 |
zinc finger RANBP2-type containing 2 |
increases expression |
ISO |
fenpyroximate results in increased expression of ZRANB2 mRNA |
CTD |
PMID:33512557 |
|
NCBI chr 2:246,573,110...246,586,942
Ensembl chr 2:246,573,166...246,586,942
|
|
|
G |
Acat1 |
acetyl-CoA acetyltransferase 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ACAT1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 8:53,979,813...54,008,861
Ensembl chr 8:53,979,813...54,008,855
|
|
G |
Acsf2 |
acyl-CoA synthetase family member 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of ACSF2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:79,504,510...79,546,714
Ensembl chr10:79,504,511...79,546,673
|
|
G |
Acss2 |
acyl-CoA synthetase short-chain family member 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ACSS2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:144,003,808...144,047,452
Ensembl chr 3:144,004,336...144,059,675
|
|
G |
Adgrg1 |
adhesion G protein-coupled receptor G1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of ADGRG1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr19:10,003,963...10,041,122
Ensembl chr19:10,003,975...10,041,108
|
|
G |
Adora2b |
adenosine A2B receptor |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ADORA2B mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:46,940,394...46,956,772
Ensembl chr10:46,940,384...46,956,772
|
|
G |
Ahnak2 |
AHNAK nucleoprotein 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of AHNAK2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 6:131,830,668...131,876,311
Ensembl chr 6:131,831,454...131,854,463
|
|
G |
Akap12 |
A-kinase anchoring protein 12 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of AKAP12 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:40,730,123...40,819,863
Ensembl chr 1:40,730,123...40,819,886
|
|
G |
Aldh1l2 |
aldehyde dehydrogenase 1 family, member L2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of ALDH1L2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:20,254,246...20,305,793
Ensembl chr 7:20,254,233...20,305,776
|
|
G |
Aldh7a1 |
aldehyde dehydrogenase 7 family, member A1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ALDH7A1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr18:50,003,242...50,042,193
Ensembl chr18:50,009,934...50,042,193
|
|
G |
Aldh9a1 |
aldehyde dehydrogenase 9 family, member A1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ALDH9A1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr13:79,505,738...79,522,539
Ensembl chr13:79,505,695...79,540,568
|
|
G |
Aldoc |
aldolase, fructose-bisphosphate C |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ALDOC mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:63,217,477...63,221,066
Ensembl chr10:63,217,451...63,221,066
|
|
G |
Angptl4 |
angiopoietin-like 4 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of ANGPTL4 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:14,550,288...14,557,797
Ensembl chr 7:14,550,311...14,556,519
|
|
G |
Anxa11 |
annexin A11 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ANXA11 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr16:1,412,373...1,457,814
Ensembl chr16:1,410,756...1,457,797
|
|
G |
Anxa2 |
annexin A2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ANXA2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 8:70,105,268...70,141,663
Ensembl chr 8:70,105,253...70,141,658
|
|
G |
Anxa8 |
annexin A8 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of ANXA8 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr16:9,397,144...9,412,072
Ensembl chr16:9,397,113...9,412,043
|
|
G |
Aox1 |
aldehyde oxidase 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of AOX1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 9:59,579,621...59,658,772
Ensembl chr 9:59,579,649...59,658,770
|
|
G |
Ap1b1 |
adaptor related protein complex 1 subunit beta 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of AP1B1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr14:79,879,482...79,930,778
Ensembl chr14:79,879,533...79,930,778
|
|
G |
Ap1s2 |
adaptor related protein complex 1 subunit sigma 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of AP1S2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr X:30,572,746...30,598,961
Ensembl chr X:30,572,751...30,597,262
|
|
G |
Ap2s1 |
adaptor related protein complex 2 subunit sigma 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of AP2S1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:77,417,496...77,428,903
Ensembl chr 1:77,417,477...77,428,905
|
|
G |
Ap3d1 |
adaptor related protein complex 3 subunit delta 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of AP3D1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:8,970,249...9,005,651
Ensembl chr 7:8,970,291...9,005,643
|
|
G |
Apbb3 |
amyloid beta precursor protein binding family B member 3 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of APBB3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr18:28,273,168...28,280,347
Ensembl chr18:28,270,545...28,280,094
|
|
G |
Arap3 |
ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 3 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ARAP3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr18:29,806,214...29,834,217
Ensembl chr18:29,807,536...29,833,555
|
|
G |
Arhgef16 |
Rho guanine nucleotide exchange factor 16 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of ARHGEF16 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:164,843,656...164,866,212
Ensembl chr 5:164,844,161...164,866,212
|
|
G |
Arid5b |
AT-rich interaction domain 5B |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ARID5B mRNA |
CTD |
PMID:29432896 |
|
NCBI chr20:20,307,731...20,490,746
Ensembl chr20:20,307,731...20,487,433
|
|
G |
Arl4a |
ARF like GTPase 4A |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ARL4A mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 6:57,079,496...57,084,156
Ensembl chr 6:57,078,812...57,085,066
|
|
G |
Arl5a |
ARF like GTPase 5A |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ARL5A mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:36,878,461...36,903,362
Ensembl chr 3:36,880,712...36,903,211
|
|
G |
Atp5mg |
ATP synthase membrane subunit G |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ATP5MG mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 8:45,225,680...45,233,630
Ensembl chr 8:45,225,686...45,233,559
|
|
G |
Atp5pf |
ATP synthase peripheral stalk subunit F6 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ATP5PF mRNA |
CTD |
PMID:29432896 |
|
NCBI chr11:23,881,594...23,889,581
Ensembl chr11:23,881,592...23,889,119
|
|
G |
Atp6v0b |
ATPase H+ transporting V0 subunit B |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of ATP6V0B mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:131,423,384...131,424,900
Ensembl chr 5:131,423,387...131,426,401
|
|
G |
Atp6v0e1 |
ATPase H+ transporting V0 subunit e1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ATP6V0E1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr10:16,479,656...16,502,732
Ensembl chr10:16,479,567...16,524,434
|
|
G |
Atp8b2 |
ATPase phospholipid transporting 8B2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of ATP8B2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:175,378,514...175,402,265
Ensembl chr 2:175,378,517...175,401,883
|
|
G |
Atp9a |
ATPase phospholipid transporting 9A (putative) |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of ATP9A mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:157,360,354...157,467,628
Ensembl chr 3:157,360,359...157,467,818
|
|
G |
B4galt5 |
beta-1,4-galactosyltransferase 5 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of B4GALT5 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 3:156,018,056...156,033,983
Ensembl chr 3:156,018,053...156,070,074
|
|
G |
Bcar3 |
BCAR3 adaptor protein, NSP family member |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of BCAR3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:210,525,260...210,638,674
Ensembl chr 2:210,525,260...210,638,798
|
|
G |
Bckdk |
branched chain ketoacid dehydrogenase kinase |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of BCKDK mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:182,515,335...182,520,007
Ensembl chr 1:182,515,327...182,536,633
|
|
G |
Bex2 |
brain expressed X-linked 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of BEX1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr X:99,019,847...99,021,375
Ensembl chr X:99,019,000...99,021,503
|
|
G |
Bhlhe40 |
basic helix-loop-helix family, member e40 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of BHLHE40 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 4:141,618,453...141,624,154
Ensembl chr 4:141,618,476...141,624,774
|
|
G |
Bik |
BCL2-interacting killer |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of BIK mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:114,672,277...114,691,296
Ensembl chr 7:114,672,277...114,691,296
|
|
G |
Bnip3 |
BCL2 interacting protein 3 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of BNIP3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:193,708,164...193,725,348
Ensembl chr 1:193,708,167...193,725,359
|
|
G |
C5h8orf88 |
similar to human chromosome 8 open reading frame 88 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of C8ORF88 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:28,330,167...28,355,691
Ensembl chr 5:28,330,206...28,357,152
|
|
G |
Cacybp |
calcyclin binding protein |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CACYBP mRNA |
CTD |
PMID:29432896 |
|
NCBI chr13:72,437,485...72,447,810
Ensembl chr13:72,437,490...72,450,177
|
|
G |
Card10 |
caspase recruitment domain family, member 10 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of CARD10 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:110,330,460...110,371,551
Ensembl chr 7:110,330,408...110,359,224
|
|
G |
Casp2 |
caspase 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CASP2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 4:71,149,632...71,167,388
Ensembl chr 4:71,149,669...71,167,379
|
|
G |
Cav2 |
caveolin 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of CAV2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 4:45,616,766...45,624,144
Ensembl chr 4:45,616,712...45,624,244
|
|
G |
Ccdc12 |
coiled-coil domain containing 12 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CCDC12 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 8:110,635,276...110,686,417
Ensembl chr 8:110,635,710...110,686,417
|
|
G |
Ccdc92 |
coiled-coil domain containing 92 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CCDC92 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr12:31,796,102...31,823,333
Ensembl chr12:31,796,684...31,823,337
|
|
G |
Ccdc93 |
coiled-coil domain containing 93 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CCDC93 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr13:32,607,618...32,675,993
Ensembl chr13:32,607,587...32,676,023
|
|
G |
Ccn2 |
cellular communication network factor 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CCN2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734
|
|
G |
Ccnd2 |
cyclin D2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of CCND2 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 4:159,966,883...159,989,261
Ensembl chr 4:159,962,363...159,989,495
|
|
G |
Cd24 |
CD24 molecule |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CD24 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr20:47,074,353...47,079,662
Ensembl chr20:47,073,512...47,079,662
|
|
G |
Cd63 |
Cd63 molecule |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of CD63 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 7:1,325,108...1,340,447
Ensembl chr 7:1,325,103...1,399,178
|
|
G |
Cd99l2 |
CD99 molecule-like 2 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CD99L2 mRNA |
CTD |
PMID:29432896 |
|
|
|
G |
Cdc20 |
cell division cycle 20 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CDC20 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 5:131,966,203...131,970,406
Ensembl chr 5:131,966,215...131,970,512
|
|
G |
Cdh1 |
cadherin 1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which affects the expression of CDH1 mRNA; [[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of CDH1 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Cdh3 |
cadherin 3 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of CDH3 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr19:34,393,596...34,444,084
Ensembl chr19:34,393,727...34,444,084
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of CDKN1A mRNA |
CTD |
PMID:29432896 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cenpa |
centromere protein A |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CENPA mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 6:25,700,142...25,711,767
Ensembl chr 6:25,700,142...25,711,675
|
|
G |
Cenpf |
centromere protein F |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CENPF mRNA |
CTD |
PMID:29432896 |
|
NCBI chr13:101,184,127...101,229,714
Ensembl chr13:101,184,127...101,229,669
|
|
G |
Cep192 |
centrosomal protein 192 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CEP192 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr18:61,373,937...61,458,405
Ensembl chr18:61,332,158...61,458,379
|
|
G |
Cfap251 |
cilia and flagella associated protein 251 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of CFAP251 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr12:33,261,622...33,337,028
Ensembl chr12:33,261,476...33,293,932
|
|
G |
Chd9 |
chromodomain helicase DNA binding protein 9 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CHD9 mRNA |
CTD |
PMID:29432896 |
|
NCBI chr19:15,941,535...16,146,220
Ensembl chr19:15,942,687...16,164,556
|
|
G |
Chrna2 |
cholinergic receptor nicotinic alpha 2 subunit |
multiple interactions |
ISO |
isobutyl alcohol affects the reaction [Acetylcholine promotes the reaction [[CHRNA2 protein binds to CHRNB4 protein] which results in increased transport of Barium]] |
CTD |
PMID:11821649 |
|
NCBI chr15:40,342,317...40,358,601
Ensembl chr15:40,342,317...40,358,601
|
|
G |
Chrnb4 |
cholinergic receptor nicotinic beta 4 subunit |
multiple interactions |
ISO |
isobutyl alcohol affects the reaction [Acetylcholine promotes the reaction [[CHRNA2 protein binds to CHRNB4 protein] which results in increased transport of Barium]] |
CTD |
PMID:11821649 |
|
NCBI chr 8:55,417,583...55,437,027
Ensembl chr 8:55,418,313...55,437,027
|
|
G |
Chtop |
chromatin target of PRMT1 |
multiple interactions |
ISO |
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of CHTOP mRNA |
CTD |
PMID:29432896 |
|
NCBI chr 2:175,981,266...175,992,820
Ensembl chr 2:175,981,271...175,992,748
|
|
|
|